

Cell-free DNA Comprises an In Vivo Nucleosome Footprint

Cell

164, 57-68

DOI: [10.1016/j.cell.2015.11.050](https://doi.org/10.1016/j.cell.2015.11.050)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical applications of liquid biopsies in gastrointestinal oncology. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 675-686.	0.6	10
3	Evaluation of Methylation Biomarkers for Detection of Circulating Tumor DNA and Application to Colorectal Cancer. <i>Genes</i> , 2016, 7, 125.	1.0	47
4	Fragment Length of Circulating Tumor DNA. <i>PLoS Genetics</i> , 2016, 12, e1006162.	1.5	502
5	The In Vitro Stability of Circulating Tumour DNA. <i>PLoS ONE</i> , 2016, 11, e0168153.	1.1	18
6	Using Targeted Sequencing of Paralogous Sequences for Noninvasive Detection of Selected Fetal Aneuploidies. <i>Clinical Chemistry</i> , 2016, 62, 1621-1629.	1.5	7
7	Origins, structures, and functions of circulating DNA in oncology. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 347-376.	2.7	586
8	New insights into the generation and role of de novo mutations in health and disease. <i>Genome Biology</i> , 2016, 17, 241.	3.8	339
9	Epigenetics in liver disease: from biology to therapeutics. <i>Gut</i> , 2016, 65, 1895-1905.	6.1	115
10	SeqMaker: A next generation sequencing simulator with variations, sequencing errors and amplification bias integrated. , 2016, , .		0
11	Leukaemia cell of origin identified by chromatin landscape of bulk tumour cells. <i>Nature Communications</i> , 2016, 7, 12166.	5.8	47
12	Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns. <i>Chronic Diseases and Translational Medicine</i> , 2016, 2, 223-230.	0.9	30
13	Nucleosome Spacing – The Baggage Tag for Cell-Free DNA. <i>Clinical Chemistry</i> , 2016, 62, 1545-1547.	1.5	1
14	Cell-free DNA fragment-size distribution analysis for non-invasive prenatal CNV prediction. <i>Bioinformatics</i> , 2016, 32, 1662-1669.	1.8	6
15	The tumour trail left in blood. <i>Nature</i> , 2016, 532, 269-271.	13.7	88
16	The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics. <i>Trends in Genetics</i> , 2016, 32, 360-371.	2.9	240
17	Nucleosome mapping in plasma DNA predicts cancer gene expression. <i>Nature Genetics</i> , 2016, 48, 1105-1106.	9.4	19
18	A Forward Look At Noninvasive Prenatal Testing. <i>Trends in Molecular Medicine</i> , 2016, 22, 958-968.	3.5	17
19	Science in Focus: Circulating Tumour DNA as a Liquid Biopsy. <i>Clinical Oncology</i> , 2016, 28, 735-738.	0.6	12

#	ARTICLE	IF	CITATIONS
20	Pondering neutrophil extracellular traps with healthy skepticism. <i>Cellular Microbiology</i> , 2016, 18, 1349-1357.	1.1	77
21	Inferring expressed genes by whole-genome sequencing of plasma DNA. <i>Nature Genetics</i> , 2016, 48, 1273-1278.	9.4	295
22	Pathologists and liquid biopsies: to be or not to be?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 601-609.	1.4	49
23	Tracing the tissue of origin of plasma DNA—feasibility and implications. <i>Annals of the New York Academy of Sciences</i> , 2016, 1376, 14-17.	1.8	7
24	Technological considerations for genome-guided diagnosis and management of cancer. <i>Genome Medicine</i> , 2016, 8, 112.	3.6	13
25	Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma. <i>Scientific Reports</i> , 2016, 6, 27859.	1.6	158
26	Prenatal and pre-implantation genetic diagnosis. <i>Nature Reviews Genetics</i> , 2016, 17, 643-656.	7.7	155
27	Fast, Accurate and Automatic Ancient Nucleosome and Methylation Maps with epiPALEOMIX. <i>Molecular Biology and Evolution</i> , 2016, 33, 3284-3298.	3.5	53
28	Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies. <i>Molecular Cancer Research</i> , 2016, 14, 898-908.	1.5	279
29	Potentials, challenges and limitations of a molecular characterization of circulating tumor DNA for the management of cancer patients. <i>Laboratoriums Medizin</i> , 2016, 40, 323-334.	0.1	1
30	Second generation noninvasive fetal genome analysis reveals de novo mutations, single-base parental inheritance, and preferred DNA ends. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8159-E8168.	3.3	142
31	Nucleic acid biomarkers of β^2 cell stress and death in type 1 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 312-317.	1.2	6
32	Circulating biomarkers to monitor cancer progression and treatment. <i>Computational and Structural Biotechnology Journal</i> , 2016, 14, 211-222.	1.9	118
33	The clinical utility of molecular genetic cancer profiling. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 827-838.	1.5	6
34	Technological advances in precision medicine and drug development. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 331-343.	0.4	9
35	“Cat”s Cradling the 3D Genome by the Act of LncRNA Transcription. <i>Molecular Cell</i> , 2016, 62, 657-664.	4.5	128
36	Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. <i>Cell</i> , 2016, 166, 88-101.	13.5	340
38	The role of enhancers in cancer. <i>Nature Reviews Cancer</i> , 2016, 16, 483-493.	12.8	320

#	ARTICLE	IF	CITATIONS
39	A nucleosome footprint reveals the source of cfDNA. <i>Nature Reviews Genetics</i> , 2016, 17, 125-125.	7.7	9
40	Use of cell free DNA in breast oncology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 266-274.	3.3	24
41	Circulating-tumor DNA as an early detection and diagnostic tool. <i>Current Opinion in Genetics and Development</i> , 2017, 42, 14-21.	1.5	84
42	Nucleosome repositioning during differentiation of a human myeloid leukemia cell line. <i>Nucleus</i> , 2017, 8, 188-204.	0.6	21
43	Liquid biopsies come of age: towards implementation of circulating tumour DNA. <i>Nature Reviews Cancer</i> , 2017, 17, 223-238.	12.8	1,786
44	Epigenome-wide association studies for cancer biomarker discovery in circulating cell-free DNA: technical advances and challenges. <i>Current Opinion in Genetics and Development</i> , 2017, 42, 48-55.	1.5	28
45	Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. <i>Clinical Biochemistry</i> , 2017, 50, 496-501.	0.8	60
46	Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. <i>Nature Genetics</i> , 2017, 49, 635-642.	9.4	384
47	Advances in Circulating Tumor DNA Analysis. <i>Advances in Clinical Chemistry</i> , 2017, 80, 73-153.	1.8	23
48	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. <i>Clinical Cancer Research</i> , 2017, 23, 3980-3993.	3.2	71
49	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	2.0	3
50	Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. <i>Nature Communications</i> , 2017, 8, 15086.	5.8	107
51	Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer-Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 525-536.	1.2	64
52	Single-Stranded DNA Library Preparation Preferentially Enriches Short Maternal DNA in Maternal Plasma. <i>Clinical Chemistry</i> , 2017, 63, 1031-1037.	1.5	24
53	Patient monitoring through liquid biopsies using circulating tumor DNA. <i>International Journal of Cancer</i> , 2017, 141, 887-896.	2.3	46
54	Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 765-770.	4.0	11
55	Precision monitoring of immunotherapies in solid organ and hematopoietic stem cell transplantation. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 272-284.	6.6	1
56	Single-stranded DNA library preparation from highly degraded DNA using <i>T4</i> DNA ligase. <i>Nucleic Acids Research</i> , 2017, 45, gkx033.	6.5	198

#	ARTICLE	IF	CITATIONS
58	Potential and Challenges of Liquid Biopsies. , 2017, , 233-261.		0
59	Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1004-1012.	0.3	45
60	Comparative analysis of 12 different kits for bisulfite conversion of circulating cell-free DNA. <i>Epigenetics</i> , 2017, 12, 626-636.	1.3	56
61	CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA. <i>Genome Biology</i> , 2017, 18, 53.	3.8	204
62	Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer. <i>Cancer Medicine</i> , 2017, 6, 962-974.	1.3	27
63	Emerging concepts in liquid biopsies. <i>BMC Medicine</i> , 2017, 15, 75.	2.3	211
64	Monitoring multiple myeloma by quantification of recurrent mutations in serum. <i>Haematologica</i> , 2017, 102, 1266-1272.	1.7	51
65	Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types. <i>Scientific Reports</i> , 2017, 7, 583.	1.6	141
66	Methylation-sensitive enrichment of minor DNA alleles using a double-strand DNA-specific nuclease. <i>Nucleic Acids Research</i> , 2017, 45, e39-e39.	6.5	22
67	AfterQC: automatic filtering, trimming, error removing and quality control for fastq data. <i>BMC Bioinformatics</i> , 2017, 18, 80.	1.2	286
68	Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer. <i>Acta Oncologica</i> , 2017, 56, 7-16.	0.8	33
69	Epigenetic reprogramming in liver fibrosis and cancer. <i>Advanced Drug Delivery Reviews</i> , 2017, 121, 124-132.	6.6	62
70	Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. <i>Nature Materials</i> , 2017, 16, 1155-1161.	13.3	641
71	Myriad Applications of Circulating Cell-Free DNA in Precision Organ Transplant Monitoring. <i>Annals of the American Thoracic Society</i> , 2017, 14, S237-S241.	1.5	34
72	The potential of liquid biopsies for the early detection of cancer. <i>Npj Precision Oncology</i> , 2017, 1, 36.	2.3	126
73	High-Definition Medicine. <i>Cell</i> , 2017, 170, 828-843.	13.5	168
74	Integrative single-cell and cell-free plasma RNA transcriptomics elucidates placental cellular dynamics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7786-E7795.	3.3	242
75	Facile single-stranded DNA sequencing of human plasma DNA via thermostable group II intron reverse transcriptase template switching. <i>Scientific Reports</i> , 2017, 7, 8421.	1.6	28

#	ARTICLE	IF	CITATIONS
76	Synthetic Circulating Cell-free DNA as Quality Control Materials for Somatic Mutation Detection in Liquid Biopsy for Cancer. <i>Clinical Chemistry</i> , 2017, 63, 1465-1475.	1.5	34
77	Quality Materials for Quality Assurance in the Analysis of Liquid Biopsy Samples. <i>Clinical Chemistry</i> , 2017, 63, 1431-1432.	1.5	6
78	Utilizing circulating tumour DNA in radiation oncology. <i>Radiotherapy and Oncology</i> , 2017, 124, 357-364.	0.3	19
79	An improved digital polymerase chain reaction protocol to capture low copy <i>KRAS</i> mutations in plasma cell-free DNA by resolving subsampling issues. <i>Molecular Oncology</i> , 2017, 11, 1448-1458.	2.1	26
80	Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 939-949.	1.1	6
81	NEBNext Direct: A Novel, Rapid, Hybridization-Based Approach for the Capture and Library Conversion of Genomic Regions of Interest. <i>Current Protocols in Molecular Biology</i> , 2017, 119, 7.30.1-7.30.24.	2.9	17
82	Application of liquid biopsy in precision medicine: opportunities and challenges. <i>Frontiers of Medicine</i> , 2017, 11, 522-527.	1.5	103
83	Technologies for analysis of circulating tumour DNA: Progress and promise. <i>TrAC - Trends in Analytical Chemistry</i> , 2017, 97, 36-49.	5.8	20
84	Direct detection of early-stage cancers using circulating tumor DNA. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	808
85	Transcription and Remodeling Produce Asymmetrically Unwrapped Nucleosomal Intermediates. <i>Molecular Cell</i> , 2017, 68, 1038-1053.e4.	4.5	104
86	Resistance to Targeted Therapies in Breast Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , .	0.1	1
87	Challenges and recommendations for epigenomics in precision health. <i>Nature Biotechnology</i> , 2017, 35, 1128-1132.	9.4	19
88	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017, 8, 1324.	5.8	584
89	Predicting treatment resistance and relapse through circulating DNA. <i>Breast</i> , 2017, 34, S31-S35.	0.9	17
90	Valproic acid alters the content and function of the cell-free DNA released by hepatocellular carcinoma (HepG2) cells in vitro. <i>Biochimie</i> , 2017, 140, 93-105.	1.3	5
91	Exploring the Potential of Cell-Free-DNA Measurements After an Exhaustive Cycle-Ergometer Test as a Marker for Performance-Related Parameters. <i>International Journal of Sports Physiology and Performance</i> , 2017, 12, 597-604.	1.1	25
92	Cell-free DNA as a post-treatment surveillance strategy: current status. <i>Seminars in Oncology</i> , 2017, 44, 330-346.	0.8	20
93	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 358-369.	1.8	9

#	ARTICLE	IF	CITATIONS
94	Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer. <i>Cancers</i> , 2017, 9, 5.	1.7	99
95	Bioinformatics Approaches for Fetal DNA Fraction Estimation in Noninvasive Prenatal Testing. <i>International Journal of Molecular Sciences</i> , 2017, 18, 453.	1.8	60
96	Mechanisms of Chromatin Remodeling and Repurposing During Extracellular Translocation. <i>Advances in Protein Chemistry and Structural Biology</i> , 2017, 106, 113-137.	1.0	8
97	Characterization of background noise in capture-based targeted sequencing data. <i>Genome Biology</i> , 2017, 18, 136.	3.8	50
98	Liquid biopsies in lung cancer—time to implement research technologies in routine care?. <i>Annals of Translational Medicine</i> , 2017, 5, 278-278.	0.7	27
99	Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of <i>KRAS</i> mutations using Intplex allele-specific PCR. <i>Oncotarget</i> , 2017, 8, 86253-86263.	0.8	64
100	Genetic profiling of cancer with circulating tumor DNA analysis. <i>Journal of Genetics and Genomics</i> , 2018, 45, 79-85.	1.7	26
101	Developing DNA methylation-based diagnostic biomarkers. <i>Journal of Genetics and Genomics</i> , 2018, 45, 87-97.	1.7	41
102	Cancer detection: Seeking signals in blood. <i>Science</i> , 2018, 359, 866-867.	6.0	58
103	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1242-1253.	1.2	120
104	Accuracy and reproducibility of fetal fraction measurement using relative quantitation at polymorphic loci with microarray. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 813-817.	0.9	16
105	The diverse origins of circulating cell-free DNA in the human body: a critical reevaluation of the literature. <i>Biological Reviews</i> , 2018, 93, 1649-1683.	4.7	202
106	Circulating cell-free nucleic acids: characteristics and applications. <i>European Journal of Human Genetics</i> , 2018, 26, 937-945.	1.4	163
107	The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. <i>Acta Diabetologica</i> , 2018, 55, 593-601.	1.2	103
108	Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges. <i>ACS Sensors</i> , 2018, 3, 540-560.	4.0	31
109	Applying genomics in heart transplantation. <i>Transplant International</i> , 2018, 31, 278-290.	0.8	8
110	The value of cell-free DNA for molecular pathology. <i>Journal of Pathology</i> , 2018, 244, 616-627.	2.1	91
111	Liquid biopsy and its role in an advanced clinical trial for lung cancer. <i>Experimental Biology and Medicine</i> , 2018, 243, 262-271.	1.1	38

#	ARTICLE	IF	CITATIONS
112	Orchid: a novel management, annotation and machine learning framework for analyzing cancer mutations. <i>Bioinformatics</i> , 2018, 34, 936-942.	1.8	16
113	Identification of the functional alteration signatures across different cancer types with support vector machine and feature analysis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 2218-2227.	1.8	20
114	DNA induction of MDM2 promotes proliferation of human renal mesangial cells and alters peripheral B cells subsets in pediatric systemic lupus erythematosus. <i>Molecular Immunology</i> , 2018, 94, 166-175.	1.0	12
115	Simultaneous Discovery of Cell-Free DNA and the Nucleosome Ladder. <i>Genetics</i> , 2018, 209, 27-29.	1.2	9
116	Circulating cell-free DNA as a biomarker of tissue injury: Assessment in a cardiac xenotransplantation model. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 967-975.	0.3	25
117	Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies: Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level Analysis. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 104-108.	1.0	34
118	The Introduction and Clinical Application of Cell-Free Tumor DNA. <i>Methods in Molecular Biology</i> , 2018, 1754, 45-65.	0.4	2
119	Circulating cell-free DNA for non-invasive cancer management. <i>Cancer Genetics</i> , 2018, 228-229, 169-179.	0.2	71
120	A Study of Cell-free DNA Fragmentation Pattern and Its Application in DNA Sample Type Classification. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2018, , 1-1.	1.9	4
121	LINE-1 Hypermethylation in Serum Cell-Free DNA of Relapsing Remitting Multiple Sclerosis Patients. <i>Molecular Neurobiology</i> , 2018, 55, 4681-4688.	1.9	24
122	Association between clinical characteristics and the diagnostic accuracy of circulating single-molecule amplification and resequencing technology on detection epidermal growth factor receptor mutation status in plasma of lung adenocarcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, .	0.9	4
123	Red Blood Cells Homeostatically Bind Mitochondrial DNA through TLR9 to Maintain Quiescence and to Prevent Lung Injury. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 470-480.	2.5	90
124	Pharmacoeugenetics and Toxicoeugenetics: Novel Mechanistic Insights and Therapeutic Opportunities. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 161-185.	4.2	45
125	Recent progress in nucleic acids isotachopheresis. <i>Journal of Separation Science</i> , 2018, 41, 236-247.	1.3	21
126	Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 220-228.	1.4	59
127	A suite of DNA methylation markers that can detect most common human cancers. <i>Epigenetics</i> , 2018, 13, 61-72.	1.3	48
128	DNase1 Does Not Appear to Play a Major Role in the Fragmentation of Plasma DNA in a Knockout Mouse Model. <i>Clinical Chemistry</i> , 2018, 64, 406-408.	1.5	34
129	Predicting DNA hybridization kinetics from sequence. <i>Nature Chemistry</i> , 2018, 10, 91-98.	6.6	146

#	ARTICLE	IF	CITATIONS
130	Molecular roles and function of circular RNAs in eukaryotic cells. Cellular and Molecular Life Sciences, 2018, 75, 1071-1098.	2.4	266
131	Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. Clinical Chemistry, 2018, 64, 317-328.	1.5	42
132	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology, 2018, 36, 1631-1641.	0.8	668
133	Emerging Concepts in Liquid Biopsy. Advances in Molecular Pathology, 2018, 1, 183-191.	0.2	0
134	New insights into structural features and optimal detection of circulating tumor DNA determined by single-strand DNA analysis. Npj Genomic Medicine, 2018, 3, 31.	1.7	71
135	Universal cancer screening: revolutionary, rational, and realizable. Npj Precision Oncology, 2018, 2, 23.	2.3	77
136	Enhanced detection of circulating tumor DNA by fragment size analysis. Science Translational Medicine, 2018, 10, .	5.8	670
137	Rapid and highly-specific generation of targeted DNA sequencing libraries enabled by linking capture probes with universal primers. PLoS ONE, 2018, 13, e0208283.	1.1	11
138	Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nature Communications, 2018, 9, 5068.	5.8	584
139	Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker. Nature Communications, 2018, 9, 4915.	5.8	135
140	Decreased DNA methylation of a CpG site in the HBAP1 gene in plasma DNA from pregnant women. PLoS ONE, 2018, 13, e0198165.	1.1	0
141	Characteristics, properties, and potential applications of circulating cell-free dna in clinical diagnostics: a focus on transplantation. Journal of Immunological Methods, 2018, 463, 27-38.	0.6	39
142	DNA as a self-antigen: nature and regulation. Current Opinion in Immunology, 2018, 55, 31-37.	2.4	30
143	Sequence analysis of cell-free DNA derived from cultured human bone osteosarcoma (143B) cells. Tumor Biology, 2018, 40, 101042831880119.	0.8	32
144	Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions. Journal of Visualized Experiments, 2018, , .	0.2	3
145	Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Computational and Structural Biotechnology Journal, 2018, 16, 370-378.	1.9	247
146	Noninvasive paternal exclusion testing for cystic fibrosis in the first five to eight weeks of gestation. Scientific Reports, 2018, 8, 15941.	1.6	1
147	Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10925-E10933.	3.3	140

#	ARTICLE	IF	CITATIONS
148	Plasma-derived cell-free mitochondrial DNA: A novel non-invasive methodology to identify mitochondrial DNA haplogroups in humans. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 332-337.	0.5	20
149	TNER: a novel background error suppression method for mutation detection in circulating tumor DNA. <i>BMC Bioinformatics</i> , 2018, 19, 387.	1.2	12
150	Fetal DNA in Maternal Plasma: An Amazing Two Decades. , 2018, , 3-5.		0
151	Maternal Constitutional and Acquired Copy Number Variations. , 2018, , 179-188.		1
152	Extracellular DNA in plasma: From marking to dissecting the cell biology of cardiac transplants. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 945-947.	0.3	0
153	Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy. <i>Journal of Diabetes and Metabolic Disorders</i> , 2018, 17, 19-30.	0.8	13
154	Analysis of the concentrations and size distributions of cell-free DNA in schizophrenia using fluorescence correlation spectroscopy. <i>Translational Psychiatry</i> , 2018, 8, 104.	2.4	22
155	Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5115-E5124.	3.3	114
156	Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 19-29.	0.2	41
157	Size-tagged preferred ends in maternal plasma DNA shed light on the production mechanism and show utility in noninvasive prenatal testing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5106-E5114.	3.3	107
158	Early stage NSCLC " challenges to implementing ctDNA-based screening and MRD detection. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 577-586.	12.5	281
159	Non-invasive prenatal aneuploidy testing: Critical diagnostic performance parameters predict sample z-score values. <i>Clinical Biochemistry</i> , 2018, 59, 69-77.	0.8	7
160	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from theIASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	0.5	515
161	Liquid biopsies to guide therapeutic decisions in rheumatoid arthritis. <i>Translational Research</i> , 2018, 201, 1-12.	2.2	12
162	Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. <i>PLoS ONE</i> , 2018, 13, e0197333.	1.1	55
163	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 639-650.	12.5	152
164	Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model. <i>Frontiers in Genetics</i> , 2018, 9, 6.	1.1	20
165	Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 9.	1.2	96

#	ARTICLE	IF	CITATIONS
166	The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1007.	1.8	50
167	Long Non-Coding RNAs in Neuronal Aging. <i>Non-coding RNA</i> , 2018, 4, 12.	1.3	57
168	Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 38-44.	0.9	30
169	Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum. <i>Cancers</i> , 2018, 10, 101.	1.7	53
170	Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. <i>Clinical Cancer Research</i> , 2018, 24, 6212-6222.	3.2	168
171	Rice nucleosome patterns undergo remodeling coincident with stress-induced gene expression. <i>BMC Genomics</i> , 2018, 19, 97.	1.2	12
173	The Evolving Erythrocyte: Red Blood Cells as Modulators of Innate Immunity. <i>Journal of Immunology</i> , 2018, 201, 1343-1351.	0.4	151
174	Future of Cellular and Molecular Diagnostics. , 2018, , 203-270.		2
175	A feasibility study of colorectal cancer diagnosis via circulating tumor DNA derived CNV detection. <i>PLoS ONE</i> , 2018, 13, e0196826.	1.1	22
176	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , 2018, 64, 1239-1249.	1.5	60
177	Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. <i>Cell</i> , 2018, 174, 433-447.e19.	13.5	258
178	Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. <i>Nature Communications</i> , 2018, 9, 2412.	5.8	121
179	A method for improving the accuracy of non-invasive prenatal screening by cell-free foetal DNA size selection. <i>British Journal of Biomedical Science</i> , 2018, 75, 133-138.	1.2	7
180	Epigenomic technologies for deciphering circulating tumor DNA. <i>Current Opinion in Biotechnology</i> , 2019, 55, 23-29.	3.3	9
181	Characterizing the Cancer Genome in Blood. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a026880.	2.9	7
182	Nucleosome Positioning. , 2019, , 308-317.		15
183	Detect accessible chromatin using ATAC-sequencing, from principle to applications. <i>Hereditas</i> , 2019, 156, 29.	0.5	49
184	The Prospect and Challenges to the Flow of Liquid Biopsy in Africa. <i>Cells</i> , 2019, 8, 862.	1.8	27

#	ARTICLE	IF	CITATIONS
185	Comparison of methods for the quantification of cell-free DNA isolated from cell culture supernatant. <i>Tumor Biology</i> , 2019, 41, 101042831986636.	0.8	21
186	How liquid biopsies can change clinical practice in oncology. <i>Annals of Oncology</i> , 2019, 30, 1580-1590.	0.6	231
187	Use of Circulating Tumor DNA for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 6909-6915.	3.2	34
188	Epigenetics and Type 2 Diabetes Risk. <i>Current Diabetes Reports</i> , 2019, 19, 47.	1.7	26
189	Topologic Analysis of Plasma Mitochondrial DNA Reveals the Coexistence of Both Linear and Circular Molecules. <i>Clinical Chemistry</i> , 2019, 65, 1161-1170.	1.5	19
190	Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. <i>Molecular Cancer</i> , 2019, 18, 114.	7.9	241
191	Circulating Tumor DNA and Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2019, 39, 452-462.	1.8	27
192	Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements. <i>Cells</i> , 2019, 8, 1251.	1.8	53
193	Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. <i>Cancer Cell</i> , 2019, 36, 350-368.	7.7	204
194	A novel high-throughput molecular counting method with single base-pair resolution enables accurate single-gene NIPT. <i>Scientific Reports</i> , 2019, 9, 14382.	1.6	34
195	The size of cell-free mitochondrial DNA in blood is inversely correlated with tumor burden in cancer patients. <i>Precision Clinical Medicine</i> , 2019, 2, 131-139.	1.3	24
196	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. <i>Nature Communications</i> , 2019, 10, 4666.	5.8	146
197	CTCF-dependent chromatin boundaries formed by asymmetric nucleosome arrays with decreased linker length. <i>Nucleic Acids Research</i> , 2019, 47, 11181-11196.	6.5	44
198	Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight. <i>PLoS ONE</i> , 2019, 14, e0224338.	1.1	12
199	To help aging populations, classify organismal senescence. <i>Science</i> , 2019, 366, 576-578.	6.0	42
200	Mutations found in cell-free DNA s of patients with malignant lymphoma at remission can derive from clonal hematopoiesis. <i>Cancer Science</i> , 2019, 110, 3375-3381.	1.7	16
201	DNA Methylation Cancer Biomarkers: Translation to the Clinic. <i>Frontiers in Genetics</i> , 2019, 10, 1150.	1.1	301
202	Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. <i>Nature Reviews Cancer</i> , 2019, 19, 553-567.	12.8	393

#	ARTICLE	IF	CITATIONS
203	A cell-free DNA metagenomic sequencing assay that integrates the host injury response to infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 18738-18744.	3.3	58
204	Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA. BMC Cancer, 2019, 19, 832.	1.1	110
206	Tumor heterogeneity: does it matter?. Expert Review of Anticancer Therapy, 2019, 19, 857-867.	1.1	10
207	Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. Expert Review of Hematology, 2019, 12, 959-973.	1.0	18
208	Liquid biopsies for omics-based analysis in sentinel mussels. PLoS ONE, 2019, 14, e0223525.	1.1	6
209	Cell-free nuclear, but not mitochondrial, DNA concentrations correlate with the early host inflammatory response after severe trauma. Scientific Reports, 2019, 9, 13648.	1.6	23
210	Brazilian forensic casework analysis through MPS applications: Statistical weight-of-evidence and biological nature of criminal samples as an influence factor in quality metrics. Forensic Science International, 2019, 303, 109938.	1.3	6
211	Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual. Advances in Clinical Chemistry, 2019, 89, 131-188.	1.8	9
212	Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses. Annals of Oncology, 2019, 30, 358-359.	0.6	57
213	Liquid biopsy in breast cancer: A comprehensive review. Clinical Genetics, 2019, 95, 643-660.	1.0	210
214	Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer. Cancers, 2019, 11, 805.	1.7	44
215	Cell-Free DNA. , 2019, , 11-24.		1
216	Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Critical Reviews in Oncology/Hematology, 2019, 141, 36-42.	2.0	49
217	Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 2019, 570, 385-389.	13.7	764
219	Nanopore-Assisted, Sequence-Specific Detection, and Single-Molecule Hybridization Analysis of Short, Single-Stranded DNAs. Analytical Chemistry, 2019, 91, 8630-8637.	3.2	20
220	Circulating biomarkers for early detection and clinical management of colorectal cancer. Molecular Aspects of Medicine, 2019, 69, 107-122.	2.7	214
221	Cell-free DNA diagnostics: current and emerging applications in oncology. Pharmacogenomics, 2019, 20, 357-380.	0.6	12
222	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2

#	ARTICLE	IF	CITATIONS
223	Measuring sequencer size bias using REcount: a novel method for highly accurate Illumina sequencing-based quantification. <i>Genome Biology</i> , 2019, 20, 85.	3.8	29
224	Digital Droplet PCR for Monitoring Tissue-specific Cell Death Using DNA Methylation Patterns of Circulating Cell-free DNA. <i>Current Protocols in Molecular Biology</i> , 2019, 127, e90.	2.9	19
225	Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies. <i>Journal of Hepatology</i> , 2019, 71, 409-421.	1.8	31
226	Life and death of circulating cell-free DNA. <i>Cancer Biology and Therapy</i> , 2019, 20, 1057-1067.	1.5	327
227	A Novel Multi-Biomarker Assay for Non-Invasive Quantitative Monitoring of Kidney Injury. <i>Journal of Clinical Medicine</i> , 2019, 8, 499.	1.0	29
228	IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 681-689.	1.4	30
229	Cancer Treatment in the Genomic Era. <i>Annual Review of Biochemistry</i> , 2019, 88, 247-280.	5.0	24
230	Targeted Single Primer Enrichment Sequencing with Single End Duplex-UMI. <i>Scientific Reports</i> , 2019, 9, 4810.	1.6	18
231	The emerging role of cell-free DNA as a molecular marker for cancer management. <i>Biomolecular Detection and Quantification</i> , 2019, 17, 100087.	7.0	375
232	Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma. <i>EBioMedicine</i> , 2019, 41, 427-442.	2.7	26
233	Genomic Medicine—Progress, Pitfalls, and Promise. <i>Cell</i> , 2019, 177, 45-57.	13.5	143
234	Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity. <i>Frontiers in Genetics</i> , 2019, 10, 194.	1.1	11
235	Circulating Tumor DNA: A Step into the Future of Cancer Management. <i>Acta Cytologica</i> , 2019, 63, 456-465.	0.7	13
236	Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer. <i>EBioMedicine</i> , 2019, 41, 345-356.	2.7	59
237	Cell-free tumour DNA testing for early detection of cancer—a potential future tool. <i>Journal of Internal Medicine</i> , 2019, 286, 118-136.	2.7	50
238	Generation of Highly Biomimetic Quality Control Materials for Noninvasive Prenatal Testing Based on Enzymatic Digestion of Matched Mother-Child Cell Lines. <i>Clinical Chemistry</i> , 2019, 65, 761-770.	1.5	13
239	Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1173.	1.8	28
240	Group II Intron RNPs and Reverse Transcriptases: From Retroelements to Research Tools. <i>Cold Spring Harbor Perspectives in Biology</i> , 2019, 11, a032375.	2.3	26

#	ARTICLE	IF	CITATIONS
241	An enrichment method to increase cell-free fetal DNA fraction and significantly reduce false negatives and test failures for non-invasive prenatal screening: a feasibility study. <i>Journal of Translational Medicine</i> , 2019, 17, 124.	1.8	47
242	Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. <i>Cancer Communications</i> , 2019, 39, 1-9.	3.7	53
243	Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 311-331.	1.6	123
245	Recent advances in circulating nucleic acids in oncology. <i>Annals of Oncology</i> , 2019, 30, 374-384.	0.6	69
246	Decoding genetic and epigenetic information embedded in cell free DNA with adapted SALP-seq. <i>International Journal of Cancer</i> , 2019, 145, 2395-2406.	2.3	8
247	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , 2019, 29, 418-427.	2.4	159
248	High Sensitivity Profiling of Chromatin Structure by MNase-SSP. <i>Cell Reports</i> , 2019, 26, 2465-2476.e4.	2.9	31
249	Considerations and quality controls when analyzing cell-free tumor DNA. <i>Biomolecular Detection and Quantification</i> , 2019, 17, 100078.	7.0	66
250	Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries. <i>Methods in Molecular Biology</i> , 2019, 1956, 383-435.	0.4	9
251	Pioneer Factors and Architectural Proteins Mediating Embryonic Expression Signatures in Cancer. <i>Trends in Molecular Medicine</i> , 2019, 25, 287-302.	3.5	24
252	Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA. <i>Nucleic Acids Research</i> , 2019, 47, e38-e38.	6.5	17
253	Integrated Functional Genomic Analysis Enables Annotation of Kidney Genome-Wide Association Study Loci. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 421-441.	3.0	27
254	Effect of sample type on plasma concentrations of cell-free DNA and nucleosomes in dogs. <i>Veterinary Record Open</i> , 2019, 6, e000357.	0.3	7
255	Coverage profile correction of shallow-depth circulating cell-free DNA sequencing via multidistance learning. , 2019, , .		0
256	Clonal hematopoiesis: background player in plasma cell-free DNA variants. <i>Annals of Translational Medicine</i> , 2019, 7, S384-S384.	0.7	4
257	Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients. <i>Cancers</i> , 2019, 11, 1938.	1.7	23
258	Bacterial DNA induces the formation of heat-resistant disease-associated proteins in human plasma. <i>Scientific Reports</i> , 2019, 9, 17995.	1.6	10
259	Triggers of Autoimmunity: The Role of Bacterial Infections in the Extracellular Exposure of Lupus Nuclear Autoantigens. <i>Frontiers in Immunology</i> , 2019, 10, 2608.	2.2	70

#	ARTICLE	IF	CITATIONS
260	A view on drug resistance in cancer. <i>Nature</i> , 2019, 575, 299-309.	13.7	1,391
261	High-accuracy liquid biopsies. <i>Nature Medicine</i> , 2019, 25, 1820-1821.	15.2	12
263	A ligation-based single-stranded library preparation method to analyze cell-free DNA and synthetic oligos. <i>BMC Genomics</i> , 2019, 20, 1023.	1.2	49
264	Circulating DNA, a Potentially Sensitive and Specific Diagnostic Tool for Future Medicine. <i>Dose-Response</i> , 2019, 17, 155932581989101.	0.7	1
265	Progress toward liquid biopsies in pediatric solid tumors. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 553-571.	2.7	32
266	Molecular genetic analysis reveals atypical confined placental mosaicism with a small supernumerary marker chromosome derived from chromosome 18: A clinical report of discordant results from three prenatal tests. <i>European Journal of Medical Genetics</i> , 2019, 62, 103533.	0.7	3
267	Cell-Free DNA: Applications in Different Diseases. <i>Methods in Molecular Biology</i> , 2019, 1909, 3-12.	0.4	37
268	Quantitative Methylation-Specific PCR: A Simple Method for Studying Epigenetic Modifications of Cell-Free DNA. <i>Methods in Molecular Biology</i> , 2019, 1909, 137-162.	0.4	8
269	Cell-Free DNA: An Overview of Sample Types and Isolation Procedures. <i>Methods in Molecular Biology</i> , 2019, 1909, 13-27.	0.4	29
271	Cell-Free DNA as a biomarker of aging. <i>Aging Cell</i> , 2019, 18, e12890.	3.0	80
272	Enrichment of fetal and maternal long cell-free DNA fragments from maternal plasma following DNA repair. <i>Prenatal Diagnosis</i> , 2019, 39, 88-99.	1.1	8
273	Circulating Cell-Free DNA and Cancer Therapy Monitoring: Methods and Potential. <i>Methods in Molecular Biology</i> , 2019, 1909, 31-46.	0.4	0
274	Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models. <i>Cancer Research</i> , 2019, 79, 220-230.	0.4	67
275	Current and future perspectives of liquid biopsies in genomics-driven oncology. <i>Nature Reviews Genetics</i> , 2019, 20, 71-88.	7.7	912
276	Clinical epigenetics: seizing opportunities for translation. <i>Nature Reviews Genetics</i> , 2019, 20, 109-127.	7.7	353
277	Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. <i>Journal of Thoracic Oncology</i> , 2019, 14, 16-24.	0.5	100
278	The cornerstone of integrating circulating tumor DNA into cancer management. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 1-11.	3.3	9
279	Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 195-205.	2.0	39

#	ARTICLE	IF	CITATIONS
280	Circulating DNA in Cancer Diagnosis and Prognosis. , 2019, , 207-218.		0
281	<i>Dnase1l3</i> deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 641-649.	3.3	134
282	Structural Variation Detection by Proximity Ligation from Formalin-Fixed, Paraffin-Embedded Tumor Tissue. Journal of Molecular Diagnostics, 2019, 21, 375-383.	1.2	10
283	Circulating cell-free DNA release in vitro: kinetics, size profiling, and cancer-related gene methylation. Journal of Cellular Physiology, 2019, 234, 14079-14089.	2.0	27
284	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. Cancer Treatment Reviews, 2019, 73, 73-83.	3.4	88
285	Epigenetic Biomarkers in Cell-Free DNA and Applications in Liquid Biopsy. Genes, 2019, 10, 32.	1.0	96
286	Cell-free DNA in cancer: current insights. Cellular Oncology (Dordrecht), 2019, 42, 13-28.	2.1	34
287	Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma. Annals of Hematology, 2019, 98, 255-269.	0.8	17
288	Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management. Clinical Chemistry, 2019, 65, 100-107.	1.5	16
289	Plasma DNA for early cancer detection – opportunities and challenges. Expert Review of Molecular Diagnostics, 2019, 19, 5-7.	1.5	5
290	A review of trace –Touch DNA–deposits: Variability factors and an exploration of cellular composition. Forensic Science International: Genetics, 2019, 39, 8-18.	1.6	113
291	Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. Journal of Gastroenterology, 2019, 54, 108-121.	2.3	14
292	Noninvasive Prenatal Testing for Genetic Diseases. , 2019, , 597-625.		1
293	Disease prediction by cell-free DNA methylation. Briefings in Bioinformatics, 2019, 20, 585-597.	3.2	35
294	An Efficient Trimming Algorithm based on Multi-Feature Fusion Scoring Model for NGS Data. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2020, 17, 728-738.	1.9	14
295	Overview of Molecular Testing of Cytology Specimens. Acta Cytologica, 2020, 64, 136-146.	0.7	24
296	Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?. Acta Clinica Belgica, 2020, 75, 9-18.	0.5	9
297	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2020, 22, 823-834.	1.2	29

#	ARTICLE	IF	CITATIONS
298	Tumor Liquid Biopsies. Recent Results in Cancer Research, 2020, , .	1.8	11
299	Cell-free nucleic acids and melatonin levels in human follicular fluid predict embryo quality in patients undergoing in-vitro fertilization treatment. Journal of Gynecology Obstetrics and Human Reproduction, 2020, 49, 101624.	0.6	13
300	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology, 2020, 6, 84.	3.4	66
301	Nucleic Acid Detection and Structural Investigations. Methods in Molecular Biology, 2020, , .	0.4	1
302	Should we invest in biological age predictors to treat colorectal cancer in older adults?. European Journal of Surgical Oncology, 2020, 46, 316-320.	0.5	16
303	Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. Molecular Aspects of Medicine, 2020, 72, 100828.	2.7	104
304	Advantages of Single-Stranded DNA Over Double-Stranded DNA Library Preparation for Capturing Cell-Free Tumor DNA in Plasma. Molecular Diagnosis and Therapy, 2020, 24, 95-101.	1.6	9
305	Obesity-induced nucleosome release predicts poor cardio-metabolic health. Clinical Epigenetics, 2020, 12, 2.	1.8	16
306	Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 253-269.	2.7	28
307	Tissue and Cell-Free DNA-Based Epigenomic Approaches for Cancer Detection. Clinical Chemistry, 2020, 66, 105-116.	1.5	26
308	Fetal fraction and noninvasive prenatal testing: What clinicians need to know. Prenatal Diagnosis, 2020, 40, 155-163.	1.1	82
309	Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing. Clinical Chemistry, 2020, 66, 188-198.	1.5	28
310	Hybridization chain reaction (HCR) for amplifying nanopore signals. Biosensors and Bioelectronics, 2020, 150, 111906.	5.3	39
311	DNA methylation biomarkers discovered <i>in silico</i> detect cancer in liquid biopsies from non-small cell lung cancer patients. Epigenetics, 2020, 15, 419-430.	1.3	23
312	Identification and characterization of extrachromosomal circular DNA in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1658-1665.	3.3	106
313	Reconstructing double-stranded DNA fragments on a single-molecule level reveals patterns of degradation in ancient samples. Genome Research, 2020, 30, 1449-1457.	2.4	7
314	Sarcoma treatment in the era of molecular medicine. EMBO Molecular Medicine, 2020, 12, e11131.	3.3	154
315	Liquid biopsy in lymphoma: Molecular methods and clinical applications. Cancer Treatment Reviews, 2020, 91, 102106.	3.4	45

#	ARTICLE	IF	CITATIONS
316	Cell-free DNA in plasma as an essential immune system regulator. <i>Scientific Reports</i> , 2020, 10, 17478.	1.6	24
317	Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. <i>Nature Communications</i> , 2020, 11, 3475.	5.8	341
318	Quantitative characterization of tumor cell-free DNA shortening. <i>BMC Genomics</i> , 2020, 21, 473.	1.2	13
319	New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. <i>Cancers</i> , 2020, 12, 1869.	1.7	41
320	The Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancers. <i>Cancers</i> , 2020, 12, 3343.	1.7	11
321	Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005819.	0.5	23
322	Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers. <i>IScience</i> , 2020, 23, 101844.	1.9	31
323	FinaleDB: a browser and database of cell-free DNA fragmentation patterns. <i>Bioinformatics</i> , 2021, 37, 2502-2503.	1.8	20
324	ATAC-seq with unique molecular identifiers improves quantification and footprinting. <i>Communications Biology</i> , 2020, 3, 675.	2.0	21
325	Liquid Biopsies in Renal Cell Carcinoma—Recent Advances and Promising New Technologies for the Early Detection of Metastatic Disease. <i>Frontiers in Oncology</i> , 2020, 10, 582843.	1.3	16
326	Recent advances in aptamer applications for analytical biochemistry. <i>Analytical Biochemistry</i> , 2022, 644, 113894.	1.1	18
327	Role of epigenetic alterations in aflatoxin-induced hepatocellular carcinoma. <i>Liver Cancer International</i> , 2020, 1, 41-50.	0.2	10
328	Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Cancers</i> , 2020, 12, 2041.	1.7	28
329	Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR. <i>Scientific Reports</i> , 2020, 10, 12564.	1.6	69
330	Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2020, 147, 244-251.	0.9	12
331	Tumor-specific genetic profiling and therapy in biomedicine. , 2020, , 459-485.		0
332	Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine. <i>Frontiers in Genetics</i> , 2020, 11, 844.	1.1	32
333	Detection and characterization of jagged ends of double-stranded DNA in plasma. <i>Genome Research</i> , 2020, 30, 1144-1153.	2.4	61

#	ARTICLE	IF	CITATIONS
334	Phenotypes from cell-free DNA. <i>Open Biology</i> , 2020, 10, 200119.	1.5	9
336	Evaluation of nucleosome concentrations in healthy dogs and dogs with cancer. <i>PLoS ONE</i> , 2020, 15, e0236228.	1.1	9
337	Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6827.	1.8	110
338	Illuminating the noncoding genome in cancer. <i>Nature Cancer</i> , 2020, 1, 864-872.	5.7	37
339	Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. <i>Cancers</i> , 2020, 12, 2277.	1.7	83
340	Circulating Tumor DNA in Cancer Management: A Value Proposition. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 1017-1026.	0.6	0
341	The biomolecule corona of lipid nanoparticles contains circulating cell-free DNA. <i>Nanoscale Horizons</i> , 2020, 5, 1476-1486.	4.1	19
342	Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). <i>Clinical Epigenetics</i> , 2020, 12, 126.	1.8	20
343	Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3704.	1.7	18
344	Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2441-2453.	1.1	5
345	Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8062.	1.8	103
346	Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT24.	1.5	2
347	The Utility of Liquid Biopsies in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 873-886.	0.4	14
348	Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients. <i>Cancers</i> , 2020, 12, 1222.	1.7	40
349	Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA. <i>EBioMedicine</i> , 2020, 55, 102462.	2.7	14
350	Preanalytical variables that affect the outcome of cell-free DNA measurements. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 484-507.	2.7	52
351	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. <i>Leukemia</i> , 2020, 34, 3007-3018.	3.3	26
352	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. <i>Nature Medicine</i> , 2020, 26, 1114-1124.	15.2	216

#	ARTICLE	IF	CITATIONS
353	UltraPrep is a scalable, cost-effective, bead-based method for purifying cell-free DNA. PLoS ONE, 2020, 15, e0231854.	1.1	5
354	Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors. Molecular Cancer Therapeutics, 2020, 19, 1486-1496.	1.9	18
355	Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial. BMJ Open, 2020, 10, e035284.	0.8	8
356	Epigenetic biomarkers and preterm birth. Environmental Epigenetics, 2020, 6, dvaa005.	0.9	19
357	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. Cancer Discovery, 2020, 10, 664-673.	7.7	152
358	Targeted Sequencing of Genomic Repeat Regions Detects Circulating Cell-free Echinococcus DNA. PLoS Neglected Tropical Diseases, 2020, 14, e0008147.	1.3	11
359	Assessing aneuploidy with repetitive element sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4858-4863.	3.3	50
360	Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer, 2020, 1, 276-290.	5.7	309
361	Circulating cell-free DNA is predominantly composed of retrotransposable elements and non-telomeric satellite DNA. Journal of Biotechnology, 2020, 313, 48-56.	1.9	15
362	Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors. Frontiers in Cell and Developmental Biology, 2020, 8, 45.	1.8	44
363	Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection. Scientific Reports, 2020, 10, 4124.	1.6	23
364	Manual and automated preparation of single-stranded DNA libraries for the sequencing of DNA from ancient biological remains and other sources of highly degraded DNA. Nature Protocols, 2020, 15, 2279-2300.	5.5	101
365	The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Frontiers in Molecular Biosciences, 2020, 7, 113.	1.6	52
366	Finding new cancer epigenetic and genetic biomarkers from cell-free DNA by combining SALP-seq and machine learning. Computational and Structural Biotechnology Journal, 2020, 18, 1891-1903.	1.9	13
367	Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis. Cancer Journal (Sudbury, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	15
368	Emerging Precision Oncology Applications of Liquid Biopsy using Circulating Tumour DNA and Methylome Profiling. Clinical Oncology, 2020, 32, 626-631.	0.6	1
369	cfNOME – A single assay for comprehensive epigenetic analyses of cell-free DNA. Genome Medicine, 2020, 12, 54.	3.6	39
370	The Ratio of ssDNA to dsDNA in Circulating Cell-Free DNA Extract is a Stable Indicator for Diagnosis of Gastric Cancer. Pathology and Oncology Research, 2020, 26, 2621-2632.	0.9	8

#	ARTICLE	IF	CITATIONS
371	Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	4
372	Whole-Genome Promoter Profiling of Plasma DNA Exhibits Diagnostic Value for Placenta-Origin Pregnancy Complications. <i>Advanced Science</i> , 2020, 7, 1901819.	5.6	27
373	Hemolysis and Fetal Fraction in Cell-Free DNA Blood Collection Tubes for Noninvasive Prenatal Testing. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 185-190.	1.6	5
374	Potential of Next-Generation Sequencing in Noninvasive Fetal Molecular Blood Group Genotyping. <i>Transfusion Medicine and Hemotherapy</i> , 2020, 47, 14-22.	0.7	15
375	Separating the signal from the noise in metagenomic cell-free DNA sequencing. <i>Microbiome</i> , 2020, 8, 18.	4.9	31
376	Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer. <i>PLoS ONE</i> , 2020, 15, e0227294.	1.1	8
377	Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100837.	2.7	6
378	Blood contains circulating cell-free respiratory competent mitochondria. <i>FASEB Journal</i> , 2020, 34, 3616-3630.	0.2	255
379	Cell-free circulating epimarks in cancer monitoring. <i>Epigenomics</i> , 2020, 12, 145-155.	1.0	8
380	The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. <i>American Journal of Human Genetics</i> , 2020, 106, 202-214.	2.6	127
381	Nucleosome positioning sequence patterns as packing or regulatory. <i>PLoS Computational Biology</i> , 2020, 16, e1007365.	1.5	4
382	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. <i>Science</i> , 2020, 369, .	6.0	351
383	Absolute measurement of the tissue origins of cell-free DNA in the healthy state and following paracetamol overdose. <i>BMC Medical Genomics</i> , 2020, 13, 60.	0.7	10
384	Comparison of commercially available whole-genome sequencing kits for variant detection in circulating cell-free DNA. <i>Scientific Reports</i> , 2020, 10, 6190.	1.6	13
385	Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study. <i>Cancer Biomarkers</i> , 2020, 28, 269-273.	0.8	4
386	Improvement of digital PCR conditions for direct detection of KRAS mutations. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23344.	0.9	2
387	Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3671-3690.	2.4	20
388	Cell free DNA from respiratory pathogens is detectable in the blood plasma of Cystic Fibrosis patients. <i>Scientific Reports</i> , 2020, 10, 6903.	1.6	15

#	ARTICLE	IF	CITATIONS
389	Size profile of cell-free DNA: A beacon guiding the practice and innovation of clinical testing. <i>Theranostics</i> , 2020, 10, 4737-4748.	4.6	45
390	Research in Computational Molecular Biology. <i>Lecture Notes in Computer Science</i> , 2020, , .	1.0	0
391	Tumor microenvironment complexity and therapeutic implications at a glance. <i>Cell Communication and Signaling</i> , 2020, 18, 59.	2.7	909
392	Noninvasive prediction of fetal growth restriction by whole-genome promoter profiling of maternal plasma DNA: a nested case-control study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 458-466.	1.1	9
393	Identifying the tissues-of-origin of circulating cell-free DNAs is a promising way in noninvasive diagnostics. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	15
394	Fetal mitochondrial <scp>DNA</scp> in maternal plasma in surrogate pregnancies: Detection and topology. <i>Prenatal Diagnosis</i> , 2021, 41, 368-375.	1.1	11
395	Noninvasive inferring expressed genes and in vivo monitoring of the physiology and pathology of pregnancy using cell-free DNA. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 300.e1-300.e9.	0.7	7
396	Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 199-222.	9.6	16
397	Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer. <i>Gastroenterology</i> , 2021, 160, 690-709.	0.6	112
398	Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?. <i>Cancer Communications</i> , 2021, 41, 3-15.	3.7	10
399	The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103166.	2.0	49
400	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 176-190.	157.7	101
401	Next-Generation Liquid Biopsies: Embracing Data Science in Oncology. <i>Trends in Cancer</i> , 2021, 7, 283-292.	3.8	42
402	Cell-free DNA and RNA measurement and applications in clinical diagnostics with focus on metabolic disorders. <i>Physiological Genomics</i> , 2021, 53, 33-46.	1.0	23
403	Fragmentation of cell-free DNA is induced by upper tract urothelial carcinoma-associated systemic inflammation. <i>Cancer Science</i> , 2021, 112, 168-177.	1.7	6
404	The evolution of patient-specific precision biomarkers to guide personalized heart-transplant care. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 51-63.	0.4	8
405	Towards systematic nomenclature for cell-free DNA. <i>Human Genetics</i> , 2021, 140, 565-578.	1.8	42
406	Liquid biopsy with cell free DNA: new horizons for prostate cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 60-76.	2.7	27

#	ARTICLE	IF	CITATIONS
407	Circulating cell-free DNA improves the molecular characterisation of Philadelphia-negative myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2021, 192, 300-309.	1.2	13
408	Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. <i>British Journal of Cancer</i> , 2021, 124, 345-358.	2.9	238
409	Rapid and simple single-chamber nucleic acid detection system prepared through nature-inspired surface engineering. <i>Theranostics</i> , 2021, 11, 6735-6745.	4.6	1
410	Mass spectrometry-based characterization of histones in clinical samples: applications, progress, and challenges. <i>FEBS Journal</i> , 2022, 289, 1191-1213.	2.2	20
411	Decoding the Tissue of Origin of Cellular Damage from Cell-Free DNA in Liquid Biopsies. , 2021, , 365-378.		2
413	Clinical utility of solid tumor epigenetics. , 2021, , 425-446.		0
414	Prenatal Diagnosis and Preimplantation Genetic Diagnosis. , 2021, , 769-800.		0
415	Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer. <i>Biomedicines</i> , 2021, 9, 48.	1.4	14
416	Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients. <i>Methods in Molecular Biology</i> , 2021, 2265, 247-263.	0.4	0
417	ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin. <i>Nature Biotechnology</i> , 2021, 39, 586-598.	9.4	81
418	Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid. <i>Journal of Neuro-Oncology</i> , 2021, 152, 47-54.	1.4	27
419	Nuclear Factor- κ B Activating Protein Plays an Oncogenic Role in Neuroblastoma Tumorigenesis and Recurrence Through the Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 622793.	1.8	4
420	Next-generation sequencing: an expedition from workstation to clinical applications. , 2021, , 29-47.		5
421	The Molecular Pathobiology of Malignant Process and Molecular Diagnostic Testing for Cancer. , 2021, , 3-21.		1
422	Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients. <i>Scientific Reports</i> , 2021, 11, 221.	1.6	21
423	Jagged Ends of Urinary Cell-Free DNA: Characterization and Feasibility Assessment in Bladder Cancer Detection. <i>Clinical Chemistry</i> , 2021, 67, 621-630.	1.5	24
424	Ultrasensitive hybridization capture: Reliable detection of ≤ 1 copy/mL short cell-free DNA from large-volume urine samples. <i>PLoS ONE</i> , 2021, 16, e0247851.	1.1	8
425	The role of donor-derived cell-free DNA in the detection of renal allograft injury. <i>Nephrologie Et Therapeutique</i> , 2021, 17, 12-17.	0.2	7

#	ARTICLE	IF	CITATIONS
426	Analysis of recurrently protected genomic regions in cell-free DNA found in urine. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	40
427	The Role of Nucleases and Nucleic Acid Editing Enzymes in the Regulation of Self-Nucleic Acid Sensing. <i>Frontiers in Immunology</i> , 2021, 12, 629922.	2.2	18
428	Circulating tumour DNA in B-cell lymphomas: current state and future prospects. <i>British Journal of Haematology</i> , 2021, 193, 867-881.	1.2	11
429	Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine. <i>Cancers</i> , 2021, 13, 728.	1.7	19
430	Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 622459.	1.8	31
431	Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer. <i>Molecular Cancer</i> , 2021, 20, 36.	7.9	30
432	Rationale for Early Detection of EWSR1 Translocation-Associated Sarcoma Biomarkers in Liquid Biopsy. <i>Cancers</i> , 2021, 13, 824.	1.7	3
433	Overexpression of Stat3 increases circulating cfDNA in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 69-80.	1.1	2
434	Clinical Significance of a Circulating Tumor Cell-based Classifier in Stage IB Lung Adenocarcinoma. <i>Annals of Surgery</i> , 2023, 277, e439-e448.	2.1	7
435	Exploring genetic alterations in circulating tumor DNA from cerebrospinal fluid of pediatric medulloblastoma. <i>Scientific Reports</i> , 2021, 11, 5638.	1.6	18
436	Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology. <i>ELife</i> , 2021, 10, .	2.8	19
437	Perspectives for the analysis of circulating tumor DNA in clinical oncology: achievements and unresolved issues. <i>Voprosy Onkologii</i> , 2021, 67, 29-34.	0.1	0
438	Association between the nucleosome footprint of plasma DNA and neoadjuvant chemotherapy response for breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 35.	2.3	9
439	Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 658234.	1.3	12
441	Jagged Ends of Cell-Free DNA: Rebranding Fragmentomics in Modern Liquid Biopsy Diagnostics. <i>Clinical Chemistry</i> , 2021, 67, 576-578.	1.5	3
442	Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs. <i>Frontiers in Veterinary Science</i> , 2021, 8, 664718.	0.9	21
443	Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease. <i>Cancers</i> , 2021, 13, 1265.	1.7	23
444	Deoxyribonuclease 1-Mediated Clearance of Circulating Chromatin Prevents From Immune Cell Activation and Pro-inflammatory Cytokine Production, a Phenomenon Amplified by Low Trap1 Activity: Consequences for Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021, 12, 613597.	2.2	8

#	ARTICLE	IF	CITATIONS
445	Total and endothelial cell-derived cell-free DNA in blood plasma does not change during menstruation. PLoS ONE, 2021, 16, e0250561.	1.1	9
446	Extracellular genetic materials and their application in clinical practice. Cancer Genetics, 2021, 252-253, 48-63.	0.2	2
448	Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics. JCI Insight, 2021, 6, .	2.3	47
449	Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med, 2021, 2, 411-422.e5.	2.2	41
450	The Detection of Cancer Epigenetic Traces in Cell-Free DNA. Frontiers in Oncology, 2021, 11, 662094.	1.3	4
451	DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter. Clinical Epigenetics, 2021, 13, 89.	1.8	16
452	Molecular features of tumor-derived genetic alterations in circulating cell-free DNA in virtue of autopsy analysis. Scientific Reports, 2021, 11, 8398.	1.6	3
453	Identification of cell-free DNA methylation patterns unique to the human left ventricle as a potential indicator of acute cellular rejection. Clinical Transplantation, 2021, 35, e14295.	0.8	5
454	Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science, 2021, 372, .	6.0	263
455	The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer. Current Pharmaceutical Design, 2021, 27, 942-952.	0.9	2
457	Early cancer detection from genome-wide cell-free DNA fragmentation via shuffled frog leaping algorithm and support vector machine. Bioinformatics, 2021, 37, 3099-3105.	1.8	10
458	Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden. Nature Communications, 2021, 12, 2229.	5.8	49
460	A novel urine cell-free DNA preservation solution and its application in kidney transplantation. Nephrology, 2021, 26, 684-691.	0.7	8
461	Serial profiling of cell-free DNA and nucleosome histone modifications in cell cultures. Scientific Reports, 2021, 11, 9460.	1.6	23
462	OCRDetecter: Accurately Detecting Open Chromatin Regions via Plasma Cell-Free DNA Sequencing Data. International Journal of Molecular Sciences, 2021, 22, 5802.	1.8	4
463	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. Cancers, 2021, 13, 2274.	1.7	21
464	Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nature Communications, 2021, 12, 3230.	5.8	95
465	Donor-Derived Cell-Free DNA (ddcf-DNA) and Acute Antibody-Mediated Rejection in Kidney Transplantation. Medicina (Lithuania), 2021, 57, 436.	0.8	4

#	ARTICLE	IF	CITATIONS
466	Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment. <i>Molecular Oncology</i> , 2021, 15, 1667-1682.	2.1	20
467	Transcriptional Start Site Coverage Analysis in Plasma Cell-Free DNA Reveals Disease Severity and Tissue Specificity of COVID-19 Patients. <i>Frontiers in Genetics</i> , 2021, 12, 663098.	1.1	4
468	Post-Biopsy Cell-Free DNA From Blood: An Open Window on Primary Prostate Cancer Genetics and Biology. <i>Frontiers in Oncology</i> , 2021, 11, 654140.	1.3	6
469	cfDNApipe: a comprehensive quality control and analysis pipeline for cell-free DNA high-throughput sequencing data. <i>Bioinformatics</i> , 2021, 37, 4251-4252.	1.8	5
470	Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. <i>EClinicalMedicine</i> , 2021, 35, 100856.	3.2	42
471	Utility of Next-Generation Sequencing for Deciphering Intratumor Heterogeneity in Prostate Cancer. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 101-108.	0.1	1
473	Comprehensive cell type decomposition of circulating cell-free DNA with CelFiE. <i>Nature Communications</i> , 2021, 12, 2717.	5.8	27
474	Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. <i>European Heart Journal</i> , 2021, 42, 1940-1958.	1.0	34
475	DNA Methylation Patterning and the Regulation of Beta Cell Homeostasis. <i>Frontiers in Endocrinology</i> , 2021, 12, 651258.	1.5	27
476	Liquid biopsy in lymphoma: Is it primed for clinical translation?. <i>EJHaem</i> , 2021, 2, 616-627.	0.4	6
477	Leveraging the Fragment Length of Circulating Tumour DNA to Improve Molecular Profiling of Solid Tumour Malignancies with Next-Generation Sequencing: A Pathway to Advanced Non-invasive Diagnostics in Precision Oncology?. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 389-408.	1.6	26
478	Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. <i>Nature Biotechnology</i> , 2021, 39, 1220-1227.	9.4	40
480	Cell-free DNA beyond a biomarker for rejection: Biological trigger of tissue injury and potential therapeutics. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 405-413.	0.3	28
481	Clinical utility of donor-derived cell-free DNA testing in cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 397-404.	0.3	22
482	Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. <i>Nature Biomedical Engineering</i> , 2021, 5, 586-599.	11.6	74
483	Next-Generation Sequencing of Cell-Free DNA Extracted From Pleural Effusion Supernatant: Applications and Challenges. <i>Frontiers in Medicine</i> , 2021, 8, 662312.	1.2	3
484	From Sampling to Sequencing: A Liquid Biopsy Pre-Analytic Workflow to Maximize Multi-Layer Genomic Information from a Single Tube. <i>Cancers</i> , 2021, 13, 3002.	1.7	15
485	Circulating tumor DNA analysis for tumor diagnosis. <i>Talanta</i> , 2021, 228, 122220.	2.9	20

#	ARTICLE	IF	CITATIONS
486	An Improved Detection of Circulating Tumor DNA in Extracellular Vesicles-Depleted Plasma. <i>Frontiers in Oncology</i> , 2021, 11, 691798.	1.3	3
488	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. <i>European Urology</i> , 2021, 79, 762-771.	0.9	47
489	Circulating mitochondrial DNA is a proinflammatory DAMP in sickle cell disease. <i>Blood</i> , 2021, 137, 3116-3126.	0.6	51
490	ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC). <i>Cancers</i> , 2021, 13, 2869.	1.7	19
491	Distinct Extracellular RNA Profiles in Different Plasma Components. <i>Frontiers in Genetics</i> , 2021, 12, 564780.	1.1	7
492	cfDNA Sequencing: Technological Approaches and Bioinformatic Issues. <i>Pharmaceuticals</i> , 2021, 14, 596.	1.7	31
493	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	5.8	68
495	Novel non-protein biomarkers for early detection of hepatocellular carcinoma. <i>Engineering</i> , 2021, 7, 1369-1369.	3.2	1
496	Detection of Cell Types Contributing to Cancer From Circulating, Cell-Free Methylated DNA. <i>Frontiers in Genetics</i> , 2021, 12, 671057.	1.1	22
497	Targeted Next-Generation Sequencing of Circulating Tumor DNA, Bone Marrow, and Peripheral Blood Mononuclear Cells in Pediatric AML. <i>Frontiers in Oncology</i> , 2021, 11, 666470.	1.3	5
499	DISMIR: Deep learning-based noninvasive cancer detection by integrating DNA sequence and methylation information of individual cell-free DNA reads. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	24
500	Pitfalls in the Detection of Donor-Derived Cell-Free DNA in Transplant Recipients. <i>Clinical Chemistry</i> , 2021, 67, 1030-1032.	1.5	3
501	Cardiomyocyte-Specific Circulating Cell-Free Methylated DNA in Esophageal Cancer Patients Treated with Chemoradiation. <i>Gastrointestinal Disorders</i> , 2021, 3, 100-112.	0.4	2
502	Technical and biological constraints on ctDNA-based genotyping. <i>Trends in Cancer</i> , 2021, 7, 995-1009.	3.8	33
503	Meta-Analysis of Circulating Cell-Free DNA's Role in the Prognosis of Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3378.	1.7	9
504	Validating cell-free DNA from supernatant for molecular diagnostics on cytology specimens. <i>Cancer Cytopathology</i> , 2021, 129, 956-965.	1.4	5
505	The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3656.	1.7	8
506	Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. <i>Cancers</i> , 2021, 13, 3600.	1.7	37

#	ARTICLE	IF	CITATIONS
507	Diagnosing Pulmonary Tuberculosis by Using Sequence-Specific Purification of Urine Cell-Free DNA. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0007421.	1.8	23
509	Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay. <i>Cancer Biology and Therapy</i> , 2021, 22, 455-464.	1.5	6
510	Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA. <i>Cancer Genetics</i> , 2021, 258-259, 93-100.	0.2	2
511	Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid. <i>JAMA Network Open</i> , 2021, 4, e2120040.	2.8	27
512	Using cell-free DNA for HCC surveillance and prognosis. <i>JHEP Reports</i> , 2021, 3, 100304.	2.6	27
514	Cell-Free DNA in Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8941.	1.8	22
515	The Nexus of cfDNA and Nuclease Biology. <i>Trends in Genetics</i> , 2021, 37, 758-770.	2.9	66
516	Aperture: alignment-free detection of structural variations and viral integrations in circulating tumor DNA. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	3
517	At Preeclampsia Diagnosis, Total Cell-Free DNA Concentration is Elevated and Correlates With Disease Severity. <i>Journal of the American Heart Association</i> , 2021, 10, e021477.	1.6	8
518	Characterizing circulating nucleosomes in the plasma of dogs with lymphoma. <i>BMC Veterinary Research</i> , 2021, 17, 276.	0.7	9
520	The relevance of liquid biopsy in surgical oncology: The application of perioperative circulating nucleic acid dynamics in improving patient outcomes. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2021, , .	0.8	1
522	Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent meal. <i>Cancer Genetics</i> , 2021, 256-257, 165-178.	0.2	5
523	Circulating Biomarkers in Glioblastoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 404-409.	1.0	4
524	Cell-free DNA diagnostics in transplantation utilizing next generation sequencing. <i>Human Immunology</i> , 2021, 82, 850-858.	1.2	9
525	<i>EGFR</i> transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP). <i>Molecular Oncology</i> , 2021, 15, 2868-2876.	2.1	7
526	Liquid biopsy: state of reproductive medicine and beyond. <i>Human Reproduction</i> , 2021, 36, 2824-2839.	0.4	7
528	HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2021, 27, 5857-5868.	3.2	38
529	Recent advances in blood-based and artificial intelligence-enhanced approaches for gastrointestinal cancer diagnosis. <i>World Journal of Gastroenterology</i> , 2021, 27, 5666-5681.	1.4	4

#	ARTICLE	IF	CITATIONS
530	Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α -Fetoprotein. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1174-1184.	1.2	14
531	Circulating Tumor DNA in Lymphoma: Principles and Future Directions. <i>Blood Cancer Discovery</i> , 2022, 3, 5-15.	2.6	25
532	Plasma metagenomic sequencing to detect and quantify bacterial DNA in ICU patients suspected of sepsis. <i>Journal of Trauma and Acute Care Surgery</i> , 2021, Publish Ahead of Print, 988-994.	1.1	2
533	Nuclease deficiencies alter plasma cell-free DNA methylation profiles. <i>Genome Research</i> , 2021, 31, 2008-2021.	2.4	4
534	Characterizing the molecular composition and diagnostic potential of <i>Mycobacterium tuberculosis</i> urinary cell-free DNA using next-generation sequencing. <i>International Journal of Infectious Diseases</i> , 2021, 112, 330-337.	1.5	3
535	Cell-free DNA TAPS provides multimodal information for early cancer detection. <i>Science Advances</i> , 2021, 7, eabh0534.	4.7	41
536	Noninvasive discrimination of benign and malignant breast lesions using genome-wide nucleosome profiles of plasma cell-free DNA. <i>Clinica Chimica Acta</i> , 2021, 520, 95-100.	0.5	3
539	Circulating tumour DNA for clinicians: current and future clinical applications. <i>Clinical Radiology</i> , 2021, 76, 737-747.	0.5	2
540	Evolutionary conservation in noncoding genomic regions. <i>Trends in Genetics</i> , 2021, 37, 903-918.	2.9	13
541	Size distribution of cell-free DNA in oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103455.	2.0	11
542	Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 161, 98-105.	0.9	82
543	Technical Aspects of Epstein-Barr Viral Load Assays. , 2021, , 65-107.		1
544	Ring-Structured DNA and RNA as Key Players <i>In Vivo</i> and <i>In Vitro</i> . <i>Bulletin of the Chemical Society of Japan</i> , 2021, 94, 141-157.	2.0	10
546	Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. <i>Advances in Cancer Research</i> , 2021, 151, 425-468.	1.9	20
547	A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 123-139.	1.5	155
548	Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer. <i>International Journal of Cancer</i> , 2021, 148, 1665-1675.	2.3	9
549	Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma. <i>Methods in Molecular Biology</i> , 2020, 2055, 155-180.	0.4	7
550	Liquid Biopsy: Translating Minimally Invasive Disease Profiling from the Lab to the Clinic. , 2019, , 145-167.		1

#	ARTICLE	IF	CITATIONS
551	Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling. Recent Results in Cancer Research, 2020, 215, 213-230.	1.8	15
552	Computational Analysis of DNA and RNA Sequencing Data Obtained from Liquid Biopsies. Recent Results in Cancer Research, 2020, 215, 347-368.	1.8	1
553	Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. Recent Results in Cancer Research, 2020, 215, 163-180.	1.8	26
554	Future Paradigm of Breast Cancer Resistance and Treatment. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 155-178.	0.1	2
555	Cancer Methylation Biomarkers in Circulating Cell-Free DNA. , 2019, , 217-245.		3
556	Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living. Trends in Molecular Medicine, 2020, 26, 519-528.	3.5	151
557	The Monitoring of Donor-derived Cell-free DNA in Kidney Transplantation. Transplantation, 2021, 105, 509-516.	0.5	34
576	Combination of RERC and ZNF671 methylation rates in circulating cell-free DNA: A novel biomarker for screening of nasopharyngeal carcinoma. Cancer Science, 2020, 111, 2536-2545.	1.7	11
577	The Length and Distribution of Plasma Cell-Free DNA Fragments in Stroke Patients. BioMed Research International, 2020, 2020, 1-6.	0.9	7
578	Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring. Cancer Research, 2018, 78, 3407-3412.	0.4	188
579	DNA methylation changes in biomarker loci occur early in cancer progression. F1000Research, 0, 8, 2106.	0.8	5
580	DNA methylation changes in biomarker loci occur early in cancer progression. F1000Research, 2019, 8, 2106.	0.8	7
581	Quantification of transplant-derived circulating cell-free DNA in absence of a donor genotype. PLoS Computational Biology, 2017, 13, e1005629.	1.5	60
582	Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients. PLoS ONE, 2016, 11, e0161012.	1.1	39
583	Cell-Free DNA Provides a Good Representation of the Tumor Genome Despite Its Biased Fragmentation Patterns. PLoS ONE, 2017, 12, e0169231.	1.1	30
584	Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting. PLoS ONE, 2017, 12, e0176241.	1.1	23
585	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 358-369.	1.8	8
586	Analysis of serum cfDNA concentration and integrity before and after surgery in patients with lung cancer. Cellular and Molecular Biology, 2019, 65, 56-63.	0.3	7

#	ARTICLE	IF	CITATIONS
587	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	15
588	Circulating nucleic acids in the plasma and serum as potential biomarkers in neurological disorders. <i>Brazilian Journal of Medical and Biological Research</i> , 2020, 53, e9881.	0.7	18
589	Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. <i>Oncotarget</i> , 2017, 8, 100831-100851.	0.8	40
590	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. <i>Cancer Biology and Medicine</i> , 2019, 16, 655-670.	1.4	95
591	Future perspectives from lung cancer pre-clinical models: new treatments are coming?. <i>Translational Lung Cancer Research</i> , 2020, 9, 2629-2644.	1.3	3
593	Cell Free DNA as an Evolving Liquid Biopsy Biomarker for Initial Diagnosis and Therapeutic Nursing in Cancer- An Evolving Aspect in Medical Biotechnology. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 112-122.	0.9	14
594	EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. <i>Anticancer Research</i> , 2017, 37, 2721-2725.	0.5	9
595	Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations. <i>International Journal of Molecular and Cellular Medicine</i> , 2019, 8, 19-29.	1.1	9
597	Role of liquid biopsy for thoracic cancers immunotherapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 183-199.	0.5	5
598	Cell-free DNA as a liquid biopsy for early detection of gastric cancer (Review). <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	18
599	Liquid Biopsy in Liquid Tumors. <i>Journal of Cancer Therapy</i> , 2017, 08, 302-320.	0.1	5
600	Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer. <i>Soci�t� Internationale D'urologie Journal</i> , 2020, 1, 39-48.	0.2	3
601	Massively multiplex single-molecule oligonucleosome footprinting. <i>ELife</i> , 2020, 9, .	2.8	55
602	Identification of protein-protected mRNA fragments and structured excised intron RNAs in human plasma by TGIRT-seq peak calling. <i>ELife</i> , 2020, 9, .	2.8	20
603	Hyperoxaluria. , 2021, , 1-16.		0
605	Liquid Biopsies for Molecular Biology-Based Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11267.	1.8	4
606	Feasibility of Droplet Digital PCR Analysis of Plasma Cell-Free DNA From Kidney Transplant Patients. <i>Frontiers in Medicine</i> , 2021, 8, 748668.	1.2	5
607	Signatures Beyond Oncogenic Mutations in Cell-Free DNA Sequencing for Non-Invasive, Early Detection of Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 759832.	1.1	1

#	ARTICLE	IF	CITATIONS
608	Investigation of circulating DNA integrity after blood collection. <i>BioTechniques</i> , 2021, 71, 550-555.	0.8	2
609	Calibration-free NGS quantitation of mutations below 0.01% VAF. <i>Nature Communications</i> , 2021, 12, 6123.	5.8	13
610	Short single-stranded DNAs with putative non-canonical structures comprise a new class of plasma cell-free DNA. <i>BMC Biology</i> , 2021, 19, 225.	1.7	19
611	Cell-free Nucleic Acids in Cancer. <i>Advances in Molecular Pathology</i> , 2021, 4, 187-198.	0.2	1
614	Existing and Emerging Molecular Technologies in Myeloid Neoplasms. <i>Molecular Pathology Library</i> , 2018, , 369-412.	0.1	0
615	Circulating Molecular and Cellular Biomarkers in Cancer. , 0, , 607-656.		1
616	Nukleosomen. , 2018, , 1-2.		0
623	Nukleosomen. <i>Springer Reference Medizin</i> , 2019, , 1770-1771.	0.0	0
637	Estimating the Rate of Cell Type Degeneration from Epigenetic Sequencing of Cell-Free DNA. <i>Lecture Notes in Computer Science</i> , 2020, , 240-242.	1.0	0
638	Extracellular RNA in human health and disease. , 2020, , 139-161.		0
640	La biopsia líquida en el manejo del cáncer: una nueva herramienta revolucionaria de la medicina de precisión, aún con limitaciones. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	0
641	URMAP, an ultra-fast read mapper. <i>PeerJ</i> , 2020, 8, e9338.	0.9	9
644	Molecular analysis of circulating tumor DNA from breast cancer patients before and after surgery and following adjuvant chemotherapy. <i>Molecular and Clinical Oncology</i> , 2020, 13, 26.	0.4	1
645	Liquid biopsy of pancreatic tumors: Challenges for early detection and surveillance based on the molecular landscape during early carcinogenesis. <i>Suizo</i> , 2020, 35, 302-312.	0.1	2
646	Next-Generation Sequencing as an Auxiliary Tool in Pediatric Laryngeal Lymphoma Diagnosis. <i>Pediatrics</i> , 2021, 148, e2020047662.	1.0	0
647	Peritoneal Effluent Cell-Free DNA Sequencing in Peritoneal Dialysis Patients With and Without Peritonitis. <i>Kidney Medicine</i> , 2022, 4, 100383.	1.0	2
648	Enhanced Detection of Genitourinary Cancers Using Fragmentation and Copy Number Profiles Obtained from Urinary Cell-Free DNA. <i>Clinical Chemistry</i> , 2021, 67, 394-403.	1.5	5
651	Global Characterization of Circulating Nucleic Acids. <i>Methods in Molecular Biology</i> , 2020, 2063, 257-268.	0.4	0

#	ARTICLE	IF	CITATIONS
654	The role of cell free DNA and liquid biopsies in haematological conditions. , 2020, 3, 521-531.		2
655	Cancer Detection from Plasma Cell-Free DNA. E3S Web of Conferences, 2020, 218, 03049.	0.2	1
657	Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1451-1459.	1.4	3
658	High-Throughput Nucleotide Resolution Predictions of Assay Limitations Increase the Reliability and Concordance of Clinical Tests. JCO Clinical Cancer Informatics, 2021, 5, 1085-1095.	1.0	4
659	Liquid biopsy: Novel perspectives on the importance and spectrum of <i>PIK3CA</i> and <i>RET</i> mutations in solid tumors. Molecular and Clinical Oncology, 2021, 16, 1.	0.4	1
660	The Role and Impact of Minimal Residual Disease in NSCLC. Current Oncology Reports, 2021, 23, 136.	1.8	13
661	The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma. ELife, 2021, 10, .	2.8	34
669	Mutation detection using plasma circulating tumor DNA (ctDNA) in a cohort of asymptomatic adults at increased risk for cancer. International Journal of Molecular Epidemiology and Genetics, 2018, 9, 1-12.	0.4	10
670	Deoxyribonuclease 1-like 3 Inhibits Hepatocellular Carcinoma Progression by Inducing Apoptosis and Reprogramming Glucose Metabolism. International Journal of Biological Sciences, 2022, 18, 82-95.	2.6	15
671	Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer. Cancers, 2021, 13, 5615.	1.7	20
672	Circulating tumor cells in colorectal cancer in the era of precision medicine. Journal of Molecular Medicine, 2022, 100, 197-213.	1.7	12
674	Cell-free DNA technologies for the analysis of brain cancer. British Journal of Cancer, 2022, 126, 371-378.	2.9	24
675	At the dawn: cell-free DNA fragmentomics and gene regulation. British Journal of Cancer, 2022, 126, 379-390.	2.9	27
676	Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors. Cancers, 2021, 13, 5698.	1.7	31
677	A Deep-Learning Pipeline for TSS Coverage Imputation From Shallow Cell-Free DNA Sequencing. Frontiers in Medicine, 2021, 8, 684238.	1.2	0
678	Novel omics technology driving translational research in precision oncology. Advances in Genetics, 2021, 108, 81-145.	0.8	3
679	State-of-the-art nanotechnologies for the detection, recovery, analysis and elimination of liquid biopsy components in cancer. Nano Today, 2022, 42, 101361.	6.2	24
680	Determination of Expression Signature and Proportion of mtDNA in Plasma Fractions in Patients with Renal Cell Carcinoma. , 2020, 76, .		1

#	ARTICLE	IF	CITATIONS
681	Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content. <i>BMC Cancer</i> , 2022, 22, 85.	1.1	9
683	NucPosDB: a database of nucleosome positioning in vivo and nucleosomics of cell-free DNA. <i>Chromosoma</i> , 2022, 131, 19-28.	1.0	14
684	Using all our genomes: Blood-based liquid biopsies for the early detection of cancer. <i>View</i> , 2022, 3, .	2.7	21
685	Increased Circulating Cell-Free DNA in Eosinophilic Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and Immunothrombosis. <i>Frontiers in Immunology</i> , 2021, 12, 801897.	2.2	28
686	Recent Advances in Device Engineering and Computational Analysis for Characterization of Cell-Released Cancer Biomarkers. <i>Cancers</i> , 2022, 14, 288.	1.7	11
687	Deep cfDNA fragment end profiling enables cancer detection. <i>Molecular Cancer</i> , 2022, 21, 26.	7.9	17
688	Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer. <i>IScience</i> , 2022, 25, 103826.	1.9	13
689	Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. <i>Nature Biomedical Engineering</i> , 2022, 6, 232-245.	11.6	56
692	Integrated 5-hydroxymethylcytosine and fragmentation signatures as enhanced biomarkers in lung cancer. <i>Clinical Epigenetics</i> , 2022, 14, 15.	1.8	9
693	Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
694	Bioinformatics analysis methods for cell-free DNA. <i>Computers in Biology and Medicine</i> , 2022, 143, 105283.	3.9	3
695	Liquid biopsy: the value of different bodily fluids. <i>Biomarkers in Medicine</i> , 2022, 16, 127-145.	0.6	12
696	It's all in the combination: decoding the epigenome for cancer research and diagnostics. <i>Current Opinion in Genetics and Development</i> , 2022, 73, 101899.	1.5	6
697	Liquid biopsy in bladder tumors. , 2022, , 45-65.		1
698	The Effect of Preanalytical and Physiological Variables on Cell-Free DNA Fragmentation. <i>Clinical Chemistry</i> , 2022, 68, 803-813.	1.5	16
699	“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management. <i>Oncologist</i> , 2022, 27, e393-e401.	1.9	5
700	Multicancer early detection test: Preclinical, translational, and clinical evidence—generation plan and provocative questions. <i>Cancer</i> , 2022, 128, 861-874.	2.0	7
701	Refined characterization of circulating tumor DNA through biological feature integration. <i>Scientific Reports</i> , 2022, 12, 1928.	1.6	18

#	ARTICLE	IF	CITATIONS
702	Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives. <i>Acta Oncologica</i> , 2022, 61, 523-530.	0.8	5
703	Application of cell free DNA in ART. <i>Placenta</i> , 2022, 120, 18-24.	0.7	5
704	Single-molecule sequencing reveals a large population of long cell-free DNA molecules in maternal plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	43
705	LIQUORICE: detection of epigenetic signatures in liquid biopsies based on whole-genome sequencing data. <i>Bioinformatics Advances</i> , 2022, 2, .	0.9	1
706	Research Progress of Circulation Cell-Free DNA in Clinical Diseases. <i>Advances in Clinical Medicine</i> , 2022, 12, 1446-1454.	0.0	0
710	Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease. <i>Clinical Epigenetics</i> , 2022, 14, 28.	1.8	9
711	Circulating tumor cells and cell-free tumor DNA analyses in urothelial cancer using the LiquidBiopsy platform. <i>Current Urology</i> , 2022, Publish Ahead of Print, .	0.4	1
712	Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA. <i>Blood Advances</i> , 2022, 6, 3178-3188.	2.5	6
713	High-resolution analysis for urinary DNA jagged ends. <i>Npj Genomic Medicine</i> , 2022, 7, 14.	1.7	4
714	Enhanced cancer detection from cell-free DNA. <i>Nature Biotechnology</i> , 2022, , .	9.4	2
715	Transcending Bloodâ€™ Opportunities for Alternate Liquid Biopsies in Oncology. <i>Cancers</i> , 2022, 14, 1309.	1.7	7
716	Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. <i>Frontiers in Oncology</i> , 2022, 12, 802579.	1.3	5
717	NXN Gene Epigenetic Changes in an Adult Neurogenesis Model of Alzheimerâ€™s Disease. <i>Cells</i> , 2022, 11, 1069.	1.8	3
718	Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. <i>Molecular Cancer</i> , 2022, 21, 79.	7.9	219
719	Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 253-253.	0.7	2
720	Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis. <i>Clinical Cancer Research</i> , 2022, 28, 1180-1191.	3.2	30
721	A clinicianâ€™s handbook for using ctDNA throughout the patient journey. <i>Molecular Cancer</i> , 2022, 21, 81.	7.9	43
722	The many facets of liquid biopsies in lymphoma. <i>Blood</i> , 2022, 139, 1780-1781.	0.6	4

#	ARTICLE	IF	CITATIONS
723	Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 836891.	1.3	5
724	Clinical and genomic features of Chinese lung cancer patients with germline mutations. <i>Nature Communications</i> , 2022, 13, 1268.	5.8	12
725	Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. <i>Blood</i> , 2022, 139, 1863-1877.	0.6	43
726	The Potential of Circulating Cell-Free DNA Methylation as an Epilepsy Biomarker. <i>Frontiers in Cellular Neuroscience</i> , 2022, 16, 852151.	1.8	4
727	Inferring gene expression from cell-free DNA fragmentation profiles. <i>Nature Biotechnology</i> , 2022, 40, 585-597.	9.4	63
728	Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling. <i>Nature Communications</i> , 2022, 13, 1791.	5.8	8
729	Dimethylamino group modified polydopamine nanoparticles with positive charges to scavenge cell-free DNA for rheumatoid arthritis therapy. <i>Bioactive Materials</i> , 2022, 18, 409-420.	8.6	13
730	Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. <i>Genome Research</i> , 2022, 32, 215-227.	2.4	41
731	Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility. <i>Laboratory Investigation</i> , 2022, 102, 134-142.	1.7	11
732	Cyclosporine Induces Fenestra-Associated Injury in Human Renal Microvessels <i>In Vitro</i> . <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 196-207.	2.6	4
733	Extracellular DNA: A Missing Link in the Pathogenesis of Ectopic Mineralization. <i>Advanced Science</i> , 2022, 9, e2103693.	5.6	18
734	Methylated ccfDNA from plasma biomarkers of Alzheimer's disease using targeted bisulfite sequencing. <i>Epigenomics</i> , 2022, , .	1.0	1
736	Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia. <i>Science Advances</i> , 2022, 8, eabj1360.	4.7	2
737	Cell-Free DNA Fragmentomics in Liquid Biopsy. <i>Diagnostics</i> , 2022, 12, 978.	1.3	43
738	Current and Developing Liquid Biopsy Techniques for Breast Cancer. <i>Cancers</i> , 2022, 14, 2052.	1.7	19
739	Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4441.	1.8	30
740	Feasibility of circulating tumor DNA analysis in dogs with naturally occurring malignant and benign splenic lesions. <i>Scientific Reports</i> , 2022, 12, 6337.	1.6	3
743	Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 1809-1820.	3.2	22

#	ARTICLE	IF	CITATIONS
744	Effects of nucleases on cell-free extrachromosomal circular DNA. JCI Insight, 2022, 7, .	2.3	12
746	Donor-Derived Cell-Free DNA for the Detection of Heart Allograft Injury: The Impact of the Timing of the Liquid Biopsy. Transplant International, 2022, 35, 10122.	0.8	3
747	A computational framework to unify orthogonal information in DNA methylation and copy number aberrations in cell-free DNA for early cancer detection. Briefings in Bioinformatics, 2022, 23, .	3.2	3
748	Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA. PLoS ONE, 2022, 17, e0267389.	1.1	7
749	Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 279-298.	1.8	11
750	Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer. Npj Genomic Medicine, 2022, 7, 30.	1.7	4
751	Galaxy Dnpatterntools for Computational Analysis of Nucleosome Positioning Sequence Patterns. International Journal of Molecular Sciences, 2022, 23, 4869.	1.8	0
752	Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma. HemaSphere, 2022, 6, e727.	1.2	2
753	Circulating cell-free DNA for cancer early detection. Innovation(China), 2022, 3, 100259.	5.2	35
754	New Insights into Adjuvant Therapy for Localized Colon Cancer. Hematology/Oncology Clinics of North America, 2022, , .	0.9	1
755	Potential clinical utility of liquid biopsies in ovarian cancer. Molecular Cancer, 2022, 21, 114.	7.9	51
757	Evaluation of cfDNA as an early detection assay for dense tissue breast cancer. Scientific Reports, 2022, 12, 8458.	1.6	3
758	Single-Molecule Sequencing Enables Long Cell-Free DNA Detection and Direct Methylation Analysis for Cancer Patients. Clinical Chemistry, 2022, 68, 1151-1163.	1.5	22
759	Association of fetal fraction with hypertensive disorders of pregnancy incidence and disease severity. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100671.	1.3	3
760	ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 5631.	1.8	4
761	B cell-derived cfDNA after primary BNT162b2 mRNA vaccination anticipates memory B cells and SARS-CoV-2 neutralizing antibodies. Med, 2022, 3, 468-480.e5.	2.2	2
762	The Utility of Repetitive Cell-Free DNA in Cancer Liquid Biopsies. Diagnostics, 2022, 12, 1363.	1.3	9
763	Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. Prostate, 2022, 82, .	1.2	6

#	ARTICLE	IF	CITATIONS
764	Mutation profiles in circulating cell-free DNA predict acquired resistance to Olaparib in high-grade serous ovarian carcinoma. <i>Cancer Science</i> , 0, , .	1.7	5
765	Future directions for precision oncology in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	2
766	Cell-free DNA in lung transplantation: research tool or clinical workhorse?. <i>Current Opinion in Organ Transplantation</i> , 2022, 27, 177-183.	0.8	8
769	Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 727-48.	0.9	3
770	The rising tide of cell-free DNA profiling: from snapshot to temporal genome analysis. <i>Laboratoriums Medizin</i> , 2022, 46, 207-224.	0.1	7
771	cfDNA as a surrogate marker for COVID-19 severity in patients with influenza-like symptoms with and without SARS-CoV-2 infections in general practice: a study protocol for a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e058647.	0.8	0
772	Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice Trends. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 425-433.	1.2	1
773	Development and Validation of a Deep Learning Model to Screen for Trisomy 21 During the First Trimester From Nuchal Ultrasonographic Images. <i>JAMA Network Open</i> , 2022, 5, e2217854.	2.8	8
774	Integrating chromatin accessibility states in the design of targeted sequencing panels for liquid biopsy. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
775	Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. <i>British Journal of Cancer</i> , 2022, 127, 1394-1402.	2.9	25
776	Plasma cfDNA predictors of established bacteraemic infection. <i>Access Microbiology</i> , 2022, 4, .	0.2	2
777	Modeling Susceptibility to Cardiotoxicity in Cancer Therapy Using Human iPSC-Derived Cardiac Cells and Systems Biology. <i>Heart Failure Clinics</i> , 2022, 18, 335-347.	1.0	1
778	Microfluidics for Cancer Biomarker Discovery, Research, and Clinical Application. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 499-524.	0.8	5
779	Prenatal Diagnosis: The Main Advances in the Application of Identification of Biomarkers Based on Multi-Omics. , 0, , .		0
780	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. <i>Clinical Chemistry</i> , 2022, 68, 1164-1176.	1.5	6
781	The Influence of Proteins on Fate and Biological Role of Circulating DNA. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7224.	1.8	4
782	Cell-Free DNA as Biomarker for Sepsis by Integration of Microbial and Host Information. <i>Clinical Chemistry</i> , 2022, 68, 1184-1195.	1.5	19
784	Liquid biopsy derived circulating tumor cells and circulating tumor DNA as novel biomarkers in hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 507-518.	1.5	6

#	ARTICLE	IF	CITATIONS
786	The Role of Liquid Biopsy Analytes in Diagnosis, Treatment and Prognosis of Colorectal Cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
787	Results of a worldwide external quality assessment of cfDNA testing in lung Cancer. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
788	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022, 33, 750-768.	0.6	204
789	Liquid Biopsy in Prostate Cancer Managementâ€”Current Challenges and Future Perspectives. <i>Cancers</i> , 2022, 14, 3272.	1.7	44
791	Plasma contains ultrashort single-stranded DNA in addition to nucleosomal cell-free DNA. <i>IScience</i> , 2022, 25, 104554.	1.9	18
792	Circulating cell-free DNA and its clinical utility in cancer. <i>Laboratoriums Medizin</i> , 2022, 46, 265-272.	0.1	2
793	Integrating plasma cellâ€”free DNA with clinical laboratory results enhances the prediction of critically ill patients with COVIDâ€”19 at hospital admission. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	4
794	Fragmentomics of urinary cell-free DNA in nuclease knockout mouse models. <i>PLoS Genetics</i> , 2022, 18, e1010262.	1.5	7
795	Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	27
796	Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. <i>Nature</i> , 2022, 608, 199-208.	13.7	63
797	Unsupervised detection of fragment length signatures of circulating tumor DNA using non-negative matrix factorization. <i>ELife</i> , 0, 11, .	2.8	5
798	Circulating Cell-Free DNA Methylation Mirrors Alterationsâ€”In Cerebral Patterns in Epilepsy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
799	Tracing the Origin of Cell-Free DNA Molecules through Tissue-Specific Epigenetic Signatures. <i>Diagnostics</i> , 2022, 12, 1834.	1.3	14
800	Profiling disease and tissue-specific epigenetic signatures in cell-free DNA. <i>Laboratoriums Medizin</i> , 2022, 46, 283-294.	0.1	5
801	Serum cell-free DNA concentration as a possible prognostic marker in newly diagnosed diffuse large B-cell lymphoma. <i>Biomedical Research</i> , 2022, 43, 99-106.	0.3	1
803	When Tissue Is the Issue. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 485-496.	0.7	0
805	Cell-Free DNA Fragmentation Patterns in a Cancer Cell Line. <i>Diagnostics</i> , 2022, 12, 1896.	1.3	10
806	Transcription factorâ€”nucleosome dynamics from plasma cfDNA identifies ER-driven states in breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	8

#	ARTICLE	IF	CITATIONS
808	The evolving role of liquid biopsy in lung cancer. <i>Lung Cancer</i> , 2022, 172, 53-64.	0.9	19
809	Direct capture and sequencing reveal ultra-short single-stranded DNA in biofluids. <i>IScience</i> , 2022, 25, 105046.	1.9	3
810	Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4151.	0.3	6
811	Hyperoxaluria. , 2022, , 831-846.		0
812	Epigenomics of Type 2 Diabetes. <i>RSC Nanoscience and Nanotechnology</i> , 2022, , 53-91.	0.2	0
813	Advances in liquid biopsy in neuroblastoma. <i>Fundamental Research</i> , 2022, , .	1.6	1
814	Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 4136.	1.7	8
815	New Perspectives on the Importance of Cell-Free DNA Biology. <i>Diagnostics</i> , 2022, 12, 2147.	1.3	24
816	Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics. <i>Nature Biotechnology</i> , 2023, 41, 212-221.	9.4	24
817	Performance of whole-genome promoter nucleosome profiling of maternal plasma cell-free DNA for prenatal noninvasive prediction of fetal macrosomia: a retrospective nested case-control study in mainland China. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, .	0.9	1
818	Epigenetically Modified DNA Fragments. <i>Biomarkers in Disease</i> , 2023, , 597-613.	0.0	0
819	Molecular Monitoring of Lymphomas. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2023, 18, .	9.6	3
822	Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	12
823	Modelling clinical DNA fragmentation in the development of universal PCR-based assays for bisulfite-converted, formalin-fixed and cell-free DNA sample analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
825	Hydroxymethylation profile of cell-free DNA is a biomarker for early colorectal cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
826	Nanoparticulate cell-free DNA scavenger for treating inflammatory bone loss in periodontitis. <i>Nature Communications</i> , 2022, 13, .	5.8	28
828	Genetic deconvolution of fetal and maternal cell-free DNA in maternal plasma enables next-generation non-invasive prenatal screening. <i>Cell Discovery</i> , 2022, 8, .	3.1	7
829	Circulating Cell-Free DNA-Based Methylation Pattern in Saliva for Early Diagnosis of Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 4882.	1.7	6

#	ARTICLE	IF	CITATIONS
830	The Role of ctDNA in Gastric Cancer. <i>Cancers</i> , 2022, 14, 5105.	1.7	11
831	Epigenetic analysis of cell-free DNA by fragmentomic profiling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	28
832	Associations of genome-wide cell-free DNA fragmentation profiles with blood biochemical and hematological parameters in healthy individuals. <i>Genomics</i> , 2022, 114, 110504.	1.3	1
833	Blood-based DNA methylation signatures in cancer: A systematic review. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166583.	1.8	8
834	Integrative analysis of multi-omics data for liquid biopsy. <i>British Journal of Cancer</i> , 2023, 128, 505-518.	2.9	8
835	Uncovering Novel Prognostic Factors of Sudden Sensorineural Hearing Loss by Whole-Genome Sequencing of Cell-Free DNA. , 2022, 18, 459-464.		1
836	A hitchhiker's guide to cell-free DNA biology. <i>Neuro-Oncology Advances</i> , 2022, 4, ii6-ii14.	0.4	5
837	Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
838	Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14197.	1.8	8
839	Cell-free Nucleic Acids in Cancer. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 669-686.	0.7	0
841	Detecting Liver Cancer Using Cell-Free DNA Fragmentomes. <i>Cancer Discovery</i> , 2023, 13, 616-631.	7.7	34
842	Integrative analyses of maternal plasma cell-free DNA nucleosome footprint differences reveal chromosomal aneuploidy fetuses gene expression profile. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	0
843	Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes. <i>Cancer Discovery</i> , 2023, 13, 632-653.	7.7	13
844	Simultaneous extraction and quantification of circulating mitochondrial and nuclear DNA using a single plasma sample to predict specific molecular diagnostic implications. <i>Mitochondrion</i> , 2023, 68, 114-124.	1.6	2
845	Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA. <i>Genome Medicine</i> , 2022, 14, .	3.6	9
846	IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	1
847	Current Trends in Liquid Biopsy Technology for Early Diagnosis of Metastatic Renal Cell Carcinoma. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 223-234.	0.1	1
850	CRAG: de novo characterization of cell-free DNA fragmentation hotspots in plasma whole-genome sequencing. <i>Genome Medicine</i> , 2022, 14, .	3.6	6

#	ARTICLE	IF	CITATIONS
851	Noninvasive prediction of axillary lymph node status in breast cancer using promoter profiling of circulating cell-free DNA. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	0
852	Single-Particle Optical Imaging for Ultrasensitive Bioanalysis. <i>Biosensors</i> , 2022, 12, 1105.	2.3	1
853	A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA. <i>Nature Communications</i> , 2022, 13, .	5.8	27
854	How to detect cancer early using cell-free DNA. <i>Cancer Cell</i> , 2022, 40, 1464-1466.	7.7	4
855	Mesangial cell: A hub in lupus nephritis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
856	Diagnostic Potential of Minimally Invasive Biomarkers: A Biopsy-centered Viewpoint From the Banff Minimally Invasive Diagnostics Working Group. <i>Transplantation</i> , 2023, 107, 45-52.	0.5	6
857	Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA. <i>Clinical Epigenetics</i> , 2023, 15, .	1.8	4
858	Cell-Free DNA Fragmentomics: The Novel Promising Biomarker. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1503.	1.8	7
860	Circulating DNA fragmentomics and cancer screening. <i>Cell Genomics</i> , 2023, 3, 100242.	3.0	15
861	DNA methylation analysis explores the molecular basis of plasma cell-free DNA fragmentation. <i>Nature Communications</i> , 2023, 14, .	5.8	16
862	Age-related changes in antigen-specific natural antibodies are influenced by sex. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
863	Can circulating cell free DNA be a promising marker in ovarian cancer? â€œ a genome-scale profiling study in a single institution. <i>Journal of Ovarian Research</i> , 2023, 16, .	1.3	2
864	Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	15
865	Circulating cell-free DNA methylation mirrors alterations in cerebral patterns in epilepsy. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	2
866	Understanding Donor-derived Cell-free DNA in Kidney Transplantation: An Overview and Case-based Guide for Clinicians. <i>Transplantation</i> , 2023, 107, 1675-1686.	0.5	5
867	Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer. <i>Cancers</i> , 2023, 15, 96.	1.7	2
868	Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. , 2023, 11, e005924.		24
870	Application of AI in Novel Biomarkers Detection that Induces Drug Resistance, Enhance Treatment Regimens, and Advancing Precision Oncology. , 2023, , 29-48.		1

#	ARTICLE	IF	CITATIONS
871	AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology. , 2023, , 73-91.		1
872	Circulating Histones to Detect and Monitor the Progression of Cancer. International Journal of Molecular Sciences, 2023, 24, 942.	1.8	9
873	Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Molecular Cancer, 2023, 22, .	7.9	40
874	Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma. Cancer Research Communications, 2023, 3, 267-280.	0.7	4
875	Application of PCR-based approaches for evaluation of cell-free DNA fragmentation in colorectal cancer. Frontiers in Molecular Biosciences, 0, 10, .	1.6	1
876	Bridging biological cfDNA features and machine learning approaches. Trends in Genetics, 2023, 39, 285-307.	2.9	25
877	Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease. EBioMedicine, 2023, 91, 104553.	2.7	12
878	Î©-shaped fiber optic LSPR biosensor based on mismatched hybridization chain reaction and gold nanoparticles for detection of circulating cell-free DNA. Biosensors and Bioelectronics, 2023, 228, 115175.	5.3	10
879	Characterization of Cell-Free DNA Size Distribution in Osteosarcoma Patients. Clinical Cancer Research, 2023, 29, 2085-2094.	3.2	4
880	Diagnosis of echinococcosis by detecting circulating cell-free DNA and miRNA. Expert Review of Molecular Diagnostics, 2023, 23, 133-142.	1.5	1
881	Diagnostic value of cell-free DNA in thyroid cancer: A systematic review and meta-analysis. Medicine (United States), 2023, 102, e32928.	0.4	2
883	Changes in the Concentration of Extracellular DNA and Peripheral Blood Leukocytes in the Early Stages of Development of Radiation Cystitis in Rats. Biology Bulletin, 2022, 49, 2279-2284.	0.1	0
884	Cell-free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients. Molecular Oncology, 2023, 17, 722-736.	2.1	5
885	Integrated analysis toolkit for dissecting whole-genome-wide features of cell-free DNA. Clinical and Translational Medicine, 2023, 13, .	1.7	2
886	Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 102-138.	0.5	14
887	Liquid biopsy by analysis of circulating myeloma cells and cell-free nucleic acids: a novel noninvasive approach of disease evaluation in multiple myeloma. Biomarker Research, 2023, 11, .	2.8	2
888	Circulating Tumor Cells and Cell-free Nucleic Acids as Biomarkers in Colorectal Cancer. Current Pharmaceutical Design, 2023, 29, 748-765.	0.9	4
889	Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests. Cells, 2023, 12, 935.	1.8	12

#	ARTICLE	IF	CITATIONS
890	Skin and Blood Microbial Signatures of Sedentary and Migratory Trout (<i>Salmo trutta</i>) of the Kerguelen Islands. <i>Fishes</i> , 2023, 8, 174.	0.7	3
891	Understanding Head and Neck Cancer Evolution to Guide Therapeutic Approaches. , 2023, , 63-81.		0
892	Circulating and urinary tumour DNA in urothelial carcinoma“ upper tract, lower tract and metastatic disease. <i>Nature Reviews Urology</i> , 2023, 20, 406-419.	1.9	6
893	Analytical device miniaturization for the detection of circulating biomarkers. , 2023, 1, 481-498.		11
894	Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	11
895	Epigenetic liquid biopsies for minimal residual disease, what“™s around the corner?. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
896	Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA. <i>Nature Communications</i> , 2023, 14, .	5.8	5
897	Detection of HTLV-1 proviral DNA in cell-free DNA: Potential for non-invasive monitoring of Adult T cell leukaemia/lymphoma using liquid biopsy?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
898	Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7076.	1.8	3
899	Plasma cell-free DNA promise monitoring and tissue injury assessment of COVID-19. <i>Molecular Genetics and Genomics</i> , 2023, 298, 823-836.	1.0	2
900	Assessment of cell-free DNA and apoptosis in an oocyte microenvironment: promising biomarkers to predict intracytoplasmic sperm injection outcomes. <i>Zygote</i> , 0, , 1-7.	0.5	0
902	Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	10
903	Comparison of the structures and topologies of plasma extracted circulating nuclear and mitochondrial cell-free DNA. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
904	Noninvasive prenatal testing/screening by circulating cell-free DNA. , 2023, , 823-851.		0
905	Noninvasive prenatal testing for genetic diseases. , 2023, , 789-821.		0
925	The role of circulating cell-free DNA as an inflammatory mediator after stroke. <i>Seminars in Immunopathology</i> , 2023, 45, 411-425.	2.8	1
926	Liquid biopsy in cancer diagnosis, therapy and prognosis. , 2024, , 484-494.		0
939	Single-Cell Analysis Approaches in Cartilage Diseases Diagnosis and Therapies. , 2023, , 67-95.		0

#	ARTICLE	IF	CITATIONS
941	The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation. <i>Methods in Molecular Biology</i> , 2023, , 145-163.	0.4	1
951	ctDNA and Lung Cancer. <i>Current Cancer Research</i> , 2023, , 511-537.	0.2	0
958	Liquid biopsy epigenomic profiling for cancer subtyping. <i>Nature Medicine</i> , 2023, 29, 2737-2741.	15.2	7
1015	Noninvasive diagnosis of hepatocellular carcinoma by integrating the genetic, epigenetic and fragmentation features of cell-free DNAs. , 2023, , .		0
1025	Circulating Tumor DNA in Lymphoma. <i>Molecular Pathology Library</i> , 2023, , 395-426.	0.1	0